[
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Benzalkonium Chloride, 0.13% w/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Except",
        "severity": "contraindicated",
        "description": "Except in life-threatening situations, avoid this combination."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Furosemide tablets should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving high doses of salicylates concomitantly with Furosemide tablets, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "There is a risk of ototoxic effects if cisplatin and Furosemide tablets are given concomitantly."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if Furosemide tablets are not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets have a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "Lithium generally should not be given with diuretics because they reduce lithiumâ€™s renal clearance and add a high risk of lithium toxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "severe",
        "description": "Furosemide tablets combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "An interruption or reduction in the dosage of Furosemide tablets, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary."
      },
      {
        "interacting_substance": "Potentiation",
        "severity": "unknown",
        "description": "Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets may decrease arterial responsiveness to norepinephrine."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, norepinephrine may still be used effectively."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Simultaneous administration of sucralfate and Furosemide tablets may reduce the natriuretic and antihypertensive effects of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of Furosemide tablets is achieved."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "The intake of Furosemide tablets and sucralfate should be separated by at least two hours."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "In isolated cases, intravenous administration of Furosemide tablets within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Use of Furosemide tablets concomitantly with chloral hydrate is, therefore, not recommended."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Phenytoin interferes directly with renal action of Furosemide tablets."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "There is evidence that treatment with phenytoin leads to decrease intestinal absorption of Furosemide tablets, and consequently to lower peak serum furosemide concentrations."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "major",
        "description": "Methotrexate and other drugs that, like Furosemide tablets, undergo significant renal tubular secretion may reduce the effect of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Conversely, Furosemide tablets may decrease renal elimination of other drugs that undergo tubular secretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "High-dose treatment of both Furosemide tablets and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of cyclosporine and Furosemide tablets is associated with increased risk of gouty arthritis secondary to Furosemide tablets-induced hyperurecemia and cyclosporine impairment of renal urate excretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of Furosemide tablets (furosemide) in some patients by inhibiting prostaglandin synthesis."
      },
      {
        "interacting_substance": "Indomethacin",
        "severity": "unknown",
        "description": "Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both indomethacin and Furosemide tablets should be observed closely to determine if the desired diuretic and/or antihypertensive effect of Furosemide tablets is achieved."
      }
    ]
  },
  {
    "active_ingredient": "RUGBY CAPSAICIN EXTERNAL ANALGESIC - Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol, 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously."
      }
    ]
  },
  {
    "active_ingredient": "Iron (Carbonyl iron, ferrous gluconate) 90 mg Folic Acid 1 mg Vitamin B 12 (Cyanocobalamin) 12 mcg Vitamin C (Ascorbic acid) 119 mg Docusate sodium 50 mg InPovidone, croscarmellose sodium, acrylic resin, color added, magnesium stearate, FD&C Yellow No. 5, magnesium silicate, FD&C Blue No. 1, polyethylene glycol, vitamin A palmitate, ethyl vanillin.",
    "parsed_interactions": [
      {
        "interacting_substance": "Dosing",
        "severity": "moderate",
        "description": "Dosing for elderly patients should be administered with caution."
      },
      {
        "interacting_substance": "Geriatric Use",
        "severity": "unknown",
        "description": "Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range."
      },
      {
        "interacting_substance": "Prescriber",
        "severity": "unknown",
        "description": "Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones."
      }
    ]
  },
  {
    "active_ingredient": "Menthol 4% | Lidocaine 4%",
    "parsed_interactions": [
      {
        "interacting_substance": "MAO",
        "severity": "unknown",
        "description": "Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see WARNINGS )."
      },
      {
        "interacting_substance": "Cyclobenzaprine",
        "severity": "minor",
        "description": "Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and other CNS depressants."
      },
      {
        "interacting_substance": "Tricyclic",
        "severity": "unknown",
        "description": "Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds."
      },
      {
        "interacting_substance": "Tricyclic",
        "severity": "minor",
        "description": "Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (containing capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see WARNINGS AND PRECAUTIONS (5.2) ] Intervention Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS(5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Methotrexate Clinical Impact; Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see WARNINGS AND PRECAUTIONS (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Povidone Iodine 10% v/v (equivalent to 1% titratable iodine) | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers ( eg , barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol, 70% v/v Purpose Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "Lidocaine",
        "severity": "moderate",
        "description": "Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Local Anesthetics",
        "severity": "unknown",
        "description": "When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered."
      }
    ]
  },
  {
    "active_ingredient": "insulin human (rDNA origin)",
    "parsed_interactions": [
      {
        "interacting_substance": "Adjustment",
        "severity": "unknown",
        "description": "Adjustment of insulin dosage may be needed."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS Drugs that Affect Glucose Metabolism",
        "severity": "unknown",
        "description": "( 7.1 , 7.2 , 7.3 ) Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine) : Signs and symptoms of hypoglycemia may be reduced or absent."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "( 5.3 , 7.4 ) 7.1 Drugs That May Increase the Risk of Hypoglycemia The risk of hypoglycemia associated with HUMULIN 70/30 use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide)."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "minor",
        "description": "7.2 Drugs That May Decrease the Blood Glucose Lowering Effect of HUMULIN 70/30 The glucose lowering effect of HUMULIN 70/30 may be decreased when co-administered with corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "7.3 Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of HUMULIN 70/30 The glucose lowering effect of HUMULIN 70/30 may be increased or decreased when co-administered with beta-blockers, clonidine, lithium salts, and alcohol."
      },
      {
        "interacting_substance": "Pentamidine",
        "severity": "unknown",
        "description": "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "Symptoms",
        "severity": "moderate",
        "description": "7.4 Drugs That May Blunt Signs and Symptoms of Hypoglycemia The signs and symptoms of hypoglycemia [see Warnings and Precautions ( 5.3 )] may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with HUMULIN 70/30."
      }
    ]
  },
  {
    "active_ingredient": "Menthol USP 4%",
    "parsed_interactions": [
      {
        "interacting_substance": "Renal Effects",
        "severity": "unknown",
        "description": "Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Naproxen sodium and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "major",
        "description": "No significant interactions have been observed in clinical studies with naproxen and coumarin-type anticoagulants."
      },
      {
        "interacting_substance": "However",
        "severity": "moderate",
        "description": "However, caution is advised since interactions have been seen with other nonsteroidal agents of this class."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "minor",
        "description": "The free fraction of warfarin may increase substantially in some subjects and naproxen interferes with platelet function."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Isopropyl Alcohol 70% v/v Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "OTHER INGREDIENTS: Microcrystalline Cellulose, Sodium Starch Glycolate, and Stearic Acid.",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION",
        "severity": "unknown",
        "description": "This product may interact with certain prescription drugs."
      },
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION",
        "severity": "unknown",
        "description": "If you are presently taking a prescription drug, do not take this product without checking with your physician or other health professional."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 10 gr (650 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "moderate",
        "description": "Drug Interaction Precaution"
      },
      {
        "interacting_substance": "Drug Interaction Precaution Ask",
        "severity": "moderate",
        "description": "Drug Interaction Precaution Ask a physician or pharmacist before use if you are presently taking a prescription drug Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "Triple Bacitracin zinc 400 units Neomycin sulfate (5 mg equivalent to 3.5 mg Neomycin base) Polymyxin B sulfate 5000 units | BZK Wipe Benzalkonium chloride 0.13% w/v | Alcohol Wipe Isopropyl alcohol 70% | Ammonia Inhalent Ammonia 15% | PVP Wipe Povidone-iodine 10% (equivalent to 1% titratable iodine) | PAWS Ethyl alcohol 66.5% | Aspirin Aspirin 325 mg (NSAID)* *nonsteroidal anti-inflammatory drug c",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "When nabumetone tablets are administered with aspirin, its protein binding is reduced, although the clearance of free nabumetone is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of nabumetone tablets and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post marketing observations, have shown that nabumetone can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": "Diuretics",
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see"
      },
      {
        "interacting_substance": "Renal Effects",
        "severity": "unknown",
        "description": "), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "Warfarin",
        "severity": "unknown",
        "description": "In vitro studies have shown that, because of its affinity for protein, 6MNA may displace other protein-bound drugs from their binding site."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "moderate",
        "description": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "major",
        "description": "Concomitant administration of an aluminum-containing antacid had no significant effect on the bioavailability of 6MNA."
      },
      {
        "interacting_substance": "Warfarin",
        "severity": "unknown",
        "description": "When administered with food or milk, there is more rapid absorption; however, the total amount of 6MNA in the plasma is unchanged (see"
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors (see PRECAUTIONS , General , Renal Effects )."
      },
      {
        "interacting_substance": "Antacids The",
        "severity": "unknown",
        "description": "Antacids The concomitant administration of antacids has no apparent effect on the extent of absorption of etodolac."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin When etodolac is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of etodolac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine, Digoxin, Methotrexate Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Nephrotoxicity associated with cyclosporine may also be enhanced."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Patients receiving these drugs who are given etodolac, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Diuretics Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Nevertheless, clinical studies, as well as postmarketing observations have shown that etodolac can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "Glyburide Etodolac",
        "severity": "unknown",
        "description": "Glyburide Etodolac has no apparent pharmacokinetic interaction when administered with glyburide."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "Phenylbutazone Phenylbutazone",
        "severity": "unknown",
        "description": "Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac."
      },
      {
        "interacting_substance": "Although",
        "severity": "unknown",
        "description": "Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Phenytoin Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and etodolac results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with etodolac as measured by prothrombin time."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Thus, concomitant therapy with warfarin and etodolac should not require dosage adjustment of either drug."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "moderate",
        "description": "However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% Prep Pad Purpose Isopropyl Alcohol 70% v/v Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "Dosage",
        "severity": "unknown",
        "description": "Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements."
      }
    ]
  },
  {
    "active_ingredient": "Povidone-Iodine, 10% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Infections",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Infections",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Muscle Rub Menthol Methyl Salicylate",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.12) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see Warnings and Precautions (5.2) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium topical solution and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical solution and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions(5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical solution with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical solution and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical solution and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium topical solution with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium topical solution and analgesic doses of aspirin is not generally recommended."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium topical solution may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical solution in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical solution can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels."
      }
    ]
  },
  {
    "active_ingredient": "Zilactin-Benzyl alcohol 10%",
    "parsed_interactions": [
      {
        "interacting_substance": "Pharmacokinetics",
        "severity": "unknown",
        "description": "Pharmacokinetics ."
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Camphor 2%................Topical Analgesic Lidocaine 2.5%............ Topical Analgesic Methyl Salicylate 4%....Topical Analgesic (NSAID: nonsteroidal anti-inflammatory drug)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics â€‹ Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Aesculus hippocastanum 1X, Collinsonia canadensis 1X, Hamamelis virginiana 1X avenoc",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - Soothing - Paraben-Free - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Cimicifuga racemosa 6C HPUS (0.8mg), Colcynthis 6C HPUS (0.8mg), Magnesia phosphorica 6C HPUS *0.8mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - no side effects - no drug interactions - works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Dimethicone 5.0%",
    "parsed_interactions": [
      {
        "interacting_substance": "Lidocaine",
        "severity": "moderate",
        "description": "Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Local Anesthetics",
        "severity": "unknown",
        "description": "When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered."
      }
    ]
  },
  {
    "active_ingredient": "Lidocaine 4% Menthol 1%",
    "parsed_interactions": [
      {
        "interacting_substance": "Esomeprazole",
        "severity": "unknown",
        "description": "Esomeprazole magnesium decreases exposure to the active metabolite of clopidogrel."
      },
      {
        "interacting_substance": "Clopidogrel",
        "severity": "minor",
        "description": "( 7.3 ) May increase systemic exposure of cilostazol and an active metabolite."
      },
      {
        "interacting_substance": "Consider",
        "severity": "unknown",
        "description": "Consider dose reduction ( 7.3 )"
      },
      {
        "interacting_substance": "Esomeprazole",
        "severity": "minor",
        "description": "Esomeprazole magnesium may increase serum levels of tacrolimus ( 7.5 )"
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Esomeprazole magnesium may increase serum levels of methotrexate ( 7.7 ) 7.1 Interference with Antiretroviral Therapy Concomitant use of atazanavir and nelfinavir with proton pump inhibitors is not recommended."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and may result in a loss of therapeutic effect and the development of drug resistance."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "minor",
        "description": "Co-administration of saquinavir with proton pump inhibitors is expected to increase saquinavir concentrations, which may increase toxicity and require dose reduction."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with some antiretroviral drugs."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "The clinical importance and the mechanisms behind these interactions are not always known."
      },
      {
        "interacting_substance": "Increased",
        "severity": "unknown",
        "description": "Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug."
      },
      {
        "interacting_substance": "Other",
        "severity": "unknown",
        "description": "Other possible interaction mechanisms are via CYP2C19."
      },
      {
        "interacting_substance": "Reduced",
        "severity": "unknown",
        "description": "Reduced concentrations of atazanavir and nelfinavir For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole."
      },
      {
        "interacting_substance": "Following",
        "severity": "unknown",
        "description": "Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, C max by 37% and 89% and C min by 39% and 75% respectively for nelfinavir and M8."
      },
      {
        "interacting_substance": "Following",
        "severity": "unknown",
        "description": "Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hour before atazanavir), AUC was decreased by 94%, C max by 96%, and C min by 95%."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended."
      },
      {
        "interacting_substance": "Increased",
        "severity": "unknown",
        "description": "Increased concentrations of saquinavir For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported, with an increase in AUC by 82%, in C max by 75%, and in C min by 106%, following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with esomeprazole magnesium."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose reduction of saquinavir should be considered from the safety perspective for individual patients."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole."
      },
      {
        "interacting_substance": "Which Gastric",
        "severity": "unknown",
        "description": "7.2 Drugs for Which Gastric pH Can Affect Bioavailability Due to its effects on gastric acid secretion, esomeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with esomeprazole."
      },
      {
        "interacting_substance": "Esomeprazole",
        "severity": "unknown",
        "description": "Esomeprazole is an enantiomer of omeprazole."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects)."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Co-administration of digoxin with esomeprazole is expected to increase the systemic exposure of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Therefore, patients may need to be monitored when digoxin is taken concomitantly with esomeprazole."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH."
      },
      {
        "interacting_substance": "MMF",
        "severity": "unknown",
        "description": "The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving esomeprazole and MMF."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "moderate",
        "description": "Use esomeprazole with caution in transplant patients receiving MMF [see Clinical Pharmacology ( 12.3 )]."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "7.3 Effects on Hepatic Metabolism/Cytochrome P-450 Pathways Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1, and 3A4."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin, or amoxicillin."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "However, postmarketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy."
      },
      {
        "interacting_substance": "Increases",
        "severity": "minor",
        "description": "Increases in INR and prothrombin time may lead to abnormal bleeding and even death."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time."
      },
      {
        "interacting_substance": "CYP",
        "severity": "major",
        "description": "Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "unknown",
        "description": "Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam."
      },
      {
        "interacting_substance": "Clopidogrel Clopidogrel",
        "severity": "unknown",
        "description": "Clopidogrel Clopidogrel is metabolized to its active metabolite in part by CYP2C19."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use of esomeprazole 40 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant administration of esomeprazole magnesium with clopidogrel."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "When using esomeprazole magnesium, consider use of alternative anti-platelet therapy [see Clinical Pharmacology ( 12.3 ) ]."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole acts as an inhibitor of CYP2C19."
      },
      {
        "interacting_substance": "AUC",
        "severity": "unknown",
        "description": "Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased C max and AUC of cilostazol by 18% and 26% respectively."
      },
      {
        "interacting_substance": "AUC",
        "severity": "unknown",
        "description": "C max and AUC of one of its active metabolites, 3,4-dihydro-cilostazol, which has 4 to 7 times the activity of cilostazol, were increased by 29% and 69% respectively."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Co-administration of cilostazol with esomeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Therefore a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment of esomeprazole is not normally required."
      },
      {
        "interacting_substance": "Zollinger",
        "severity": "unknown",
        "description": "However, in patients with Zollinger-Ellisonâ€™s Syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampin) may lead to decreased esomeprazole serum levels."
      },
      {
        "interacting_substance": "St",
        "severity": "unknown",
        "description": "Omeprazole, of which esomeprazole is an enantiomer, has been reported to interact with St."
      },
      {
        "interacting_substance": "John",
        "severity": "unknown",
        "description": "Johnâ€™s Wort an inducer of CYP3A4."
      },
      {
        "interacting_substance": "AUC",
        "severity": "major",
        "description": "In a cross-over study in 12 healthy male subjects, St Johnâ€™s Wort (300 mg three times daily for 14 days) significantly decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (C max and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (C max and AUC decreased by 49.6 % and 43.9%, respectively)."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant use of St."
      },
      {
        "interacting_substance": "John",
        "severity": "unknown",
        "description": "Johnâ€™s Wort or rifampin with esomeprazole magnesium."
      },
      {
        "interacting_substance": "Investigations",
        "severity": "moderate",
        "description": "7.4 Interactions with Investigations of Neuroendocrine Tumors Drug-induced decrease in gastric acidity results in enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors [see Warnings and Precautions ( 5.10 ) and Clinical Pharmacology ( 12.2 ) ]."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "minor",
        "description": "7.5 Tacrolimus Concomitant administration of esomeprazole and tacrolimus may increase the serum levels of tacrolimus."
      },
      {
        "interacting_substance": "Clarithromycin Co",
        "severity": "unknown",
        "description": "7.6 Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin [see Clinical Pharmacology ( 12.4 ) ]."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "severe",
        "description": "Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [see Warnings and Precautions in prescribing information for clarithromycin ]."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "contraindicated",
        "description": "Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [see Contraindications in prescribing information for clarithromycin ]."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.7 Methotrexate Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "However, no formal drug interaction studies of methotrexate with PPIs have been conducted [see Warnings and Precautions ( 5.11 ) ]."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "These",
        "severity": "minor",
        "description": "These agents may increase the anesthetic or sedative effects of DIPRIVAN Injectable Emulsion and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids)."
      },
      {
        "interacting_substance": "DIPRIVAN Injectable Emulsion",
        "severity": "unknown",
        "description": "The concurrent administration of potent inhalational agents (e.g., isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of DIPRIVAN Injectable Emulsion."
      },
      {
        "interacting_substance": "DIPRIVAN Injectable Emulsion",
        "severity": "major",
        "description": "DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants)."
      },
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed in adults."
      },
      {
        "interacting_substance": "DIPRIVAN Injectable Emulsion",
        "severity": "severe",
        "description": "In pediatric patients, administration of fentanyl concomitantly with DIPRIVAN Injectable Emulsion may result in serious bradycardia."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Active Ingredient: Salicylic Acid 1%",
    "parsed_interactions": [
      {
        "interacting_substance": "Using",
        "severity": "minor",
        "description": "Using this product at the same time as other topical acne medications may increase dryness or irritation of the skin."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If this occurs only one medication should be used unless directed by a doctor."
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Benzoyl peroxide 4.4% | Benzoyl peroxide 4.4%",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage."
      },
      {
        "interacting_substance": "Since",
        "severity": "unknown",
        "description": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin."
      },
      {
        "interacting_substance": "Absorption",
        "severity": "unknown",
        "description": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of tetracycline may render oral contraceptives less effective."
      }
    ]
  },
  {
    "active_ingredient": "Menthol 4%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see WARNINGS AND PRECAUTIONS (5.2) ] Intervention Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS(5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Methotrexate Clinical Impact; Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see WARNINGS AND PRECAUTIONS (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in ahigher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing info)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): M onitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Blockers",
        "severity": "minor",
        "description": "C oncomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Salicylic Acid 2.0%",
    "parsed_interactions": [
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "minor",
        "description": "This product contains an alpha-hydroxy acid (AHA) that may increase skin's sensitivity to the sun and particularly thepossibility of sunburn."
      },
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "unknown",
        "description": "Use a sunscreen, wear protective clothing, and limit sun exposure while using this product and for two weeks afterwards."
      }
    ]
  },
  {
    "active_ingredient": "Calendula officinalis 1X HPUS 4% The letters \"HPUS\" indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States.",
    "parsed_interactions": [
      {
        "interacting_substance": "Keep",
        "severity": "unknown",
        "description": "Keep wounds moisturized - Paraben-free - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      }
    ]
  },
  {
    "active_ingredient": "Benzalkonium Chloride, 0.13% w/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Except",
        "severity": "contraindicated",
        "description": "Except in life-threatening situations, avoid this combination."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Furosemide tablets should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving high doses of salicylates concomitantly with Furosemide tablets, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "There is a risk of ototoxic effects if cisplatin and Furosemide tablets are given concomitantly."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if Furosemide tablets are not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets have a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "Lithium generally should not be given with diuretics because they reduce lithiumâ€™s renal clearance and add a high risk of lithium toxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "severe",
        "description": "Furosemide tablets combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "An interruption or reduction in the dosage of Furosemide tablets, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary."
      },
      {
        "interacting_substance": "Potentiation",
        "severity": "unknown",
        "description": "Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets may decrease arterial responsiveness to norepinephrine."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, norepinephrine may still be used effectively."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Simultaneous administration of sucralfate and Furosemide tablets may reduce the natriuretic and antihypertensive effects of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of Furosemide tablets is achieved."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "The intake of Furosemide tablets and sucralfate should be separated by at least two hours."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "In isolated cases, intravenous administration of Furosemide tablets within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Use of Furosemide tablets concomitantly with chloral hydrate is, therefore, not recommended."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Phenytoin interferes directly with renal action of Furosemide tablets."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "There is evidence that treatment with phenytoin leads to decrease intestinal absorption of Furosemide tablets, and consequently to lower peak serum furosemide concentrations."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "major",
        "description": "Methotrexate and other drugs that, like Furosemide tablets, undergo significant renal tubular secretion may reduce the effect of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Conversely, Furosemide tablets may decrease renal elimination of other drugs that undergo tubular secretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "High-dose treatment of both Furosemide tablets and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of Furosemide tablets."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide tablets can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of cyclosporine and Furosemide tablets is associated with increased risk of gouty arthritis secondary to Furosemide tablets-induced hyperurecemia and cyclosporine impairment of renal urate excretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of Furosemide tablets (furosemide) in some patients by inhibiting prostaglandin synthesis."
      },
      {
        "interacting_substance": "Indomethacin",
        "severity": "unknown",
        "description": "Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both indomethacin and Furosemide tablets should be observed closely to determine if the desired diuretic and/or antihypertensive effect of Furosemide tablets is achieved."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      }
    ]
  },
  {
    "active_ingredient": "Triple Bacitracin zinc 400 units Neomycin sulfate (5 mg equivalent to 3.5 mg Neomycin base) Polymyxin B sulfate 5000 units | BZK Wipe Benzalkonium chloride 0.13% w/v | Alcohol Wipe Isopropyl alcohol 70% | Ammonia Inhalent Ammonia 15% | PVP Wipe Povidone-iodine 10% (equivalent to 1% titratable iodine) | PAWS Ethyl alcohol 66.5% | Aspirin Aspirin 325 mg (NSAID)* *nonsteroidal anti-inflammatory drug c | Eyewash Sterile Water 99%",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with celecoxib."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 3:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of celecoxib capsules with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "In two studies in healthy volunteers, and in patients with osteoarthritis and established heart disease respectively, celecoxib (200-400 mg daily) has demonstrated a lack of interference with the cardioprotective antiplatelet effect of aspirin (100-325 mg)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of celecoxib capsules and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Celecoxib capsules are not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of celecoxib capsules and ACE-inhibitors or ARBs in patients who are elderly, volume- depleted, or have impaired renal function, monitor for signs of worsening renal function [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of celecoxib capsules with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of celecoxib with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Celecoxib capsules have no effect on methotrexate pharmacokinetics."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of celecoxib capsules and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of celecoxib with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of celecoxib capsules and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of celecoxib capsules and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Celecoxib",
        "severity": "unknown",
        "description": "Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver."
      },
      {
        "interacting_substance": "Inhibitors or inducers Clinical Impact",
        "severity": "unknown",
        "description": "CoÂ­-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Inhibitors or inducers Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of celecoxib."
      },
      {
        "interacting_substance": "Intervention Evaluate",
        "severity": "unknown",
        "description": "Intervention Evaluate each patient's medical history when consideration is given to prescribing celecoxib."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when celecoxib is administered with CYP2C9 inhibitors or inducers [ see Clinical Pharmacology (12.3) ]."
      },
      {
        "interacting_substance": "Inhibitors or inducers Clinical Impact",
        "severity": "unknown",
        "description": "CYP2D6 substrates"
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6 (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs."
      },
      {
        "interacting_substance": "Intervention Evaluate",
        "severity": "unknown",
        "description": "Intervention Evaluate each patient's medical history when consideration is given to prescribing celecoxib."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when celecoxib is administered with CYP2D6 substrates [ see Clinical Pharmacology (12.3) ]."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use of corticosteroids with celecoxib capsules may increase the risk of GI ulceration or bleeding."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of celecoxib capsules with corticosteroids for signs of bleeding [see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs) : Monitor patients for bleeding who are concomitantly taking celecoxib with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of celecoxib and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with celecoxib may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with celecoxib in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with celecoxib can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 2% w/v Isopropyl alcohol 70% v/v | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Aspirin 325 mg (NSAID) 1 1 nonsteroidal anti-inflammatory drug",
    "parsed_interactions": [
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "7 DRUG INTERACTIONS Cardiac Glycosides, Diuretics, and Anti-arrhythmics Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.5)] ."
      },
      {
        "interacting_substance": "Antihistamines The",
        "severity": "unknown",
        "description": "Antidepressants, Monoamine Oxidase Inhibitors, Levothyroxine, and Antihistamines The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-Adrenergic Blockers The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": "Alpha",
        "severity": "unknown",
        "description": "Alpha-Adrenergic Blockers The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot Alkaloids Ergot",
        "severity": "unknown",
        "description": "Ergot Alkaloids Ergot alkaloids may also reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Cardiac glycosides or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "( 7 ) Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "( 7 ) Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine."
      },
      {
        "interacting_substance": "Ergot alkaloids",
        "severity": "unknown",
        "description": "may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Beta",
        "severity": "severe",
        "description": "Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol Sulfate Inhalation Aerosol, but may produce severe bronchospasm in asthmatic patients."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "Therefore, patients with asthma should not normally be treated with beta-blockers."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "moderate",
        "description": "In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "The ECG changes and/or hypokalemia which may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics."
      },
      {
        "interacting_substance": "Albuterol",
        "severity": "unknown",
        "description": "Albuterol-"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear; nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol."
      },
      {
        "interacting_substance": "Albuterol Sulfate Inhalation Aerosol",
        "severity": "moderate",
        "description": "Albuterol Sulfate Inhalation Aerosol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the cardiovascular system may be potentiated."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS Ergotamine",
        "severity": "unknown",
        "description": "increased bioavailability of ergotamine."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant use."
      },
      {
        "interacting_substance": "PATIENT COUNSELING INFORMATION",
        "severity": "unknown",
        "description": "(7.2) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling."
      },
      {
        "interacting_substance": "Revised",
        "severity": "contraindicated",
        "description": "10/2021 7.1 PDE-5-Inhibitors and sGC-Stimulators Nitroglycerin sublingual tablets are contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5)."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates."
      },
      {
        "interacting_substance": "Nitroglycerin",
        "severity": "contraindicated",
        "description": "Nitroglycerin sublingual tablets are contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use can cause hypotension."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended."
      },
      {
        "interacting_substance": "Appropriate",
        "severity": "severe",
        "description": "Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "7.2 Ergotamine Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability."
      },
      {
        "interacting_substance": "Ergotamine",
        "severity": "unknown",
        "description": "Ergotamine is known to precipitate angina pectoris."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "17.1 Embryofetal Toxicity Pregnancy loss and malformations Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. Advise that they must use an acceptable form of contraception [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ]. Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate [see Use in Specific Populations (8.1) ]. Contraception Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential [see Use in Specific Populations (8.3) ]. Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence . Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended [see Use in Specific Populations (8.3) ]. For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient. Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ].",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.1) Mycophenolate mofetil may reduce effectiveness of oral contraceptives."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "Use of additional barrier contraceptive methods is recommended."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.2) See FPI for other important drug interactions."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "unknown",
        "description": "(7) 7.1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration."
      },
      {
        "interacting_substance": "PPIs",
        "severity": "unknown",
        "description": "Proton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Enterohepa",
        "severity": "unknown",
        "description": "Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepa tic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Examples Trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of mycophenolate mofetil related adverse reactions."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Examples Telmisartan",
        "severity": "unknown",
        "description": "Examples Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation)."
      },
      {
        "interacting_substance": "Calcium Free Phosph",
        "severity": "unknown",
        "description": "Calcium Free Phosph ate Binders Clinical Impact Concomitant use with calcium free phosphate binders decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "minor",
        "description": "Examples Sevelamer 7.2 Effect of Mycophenolate Mofetil on Other Drugs Table 8 Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs Drugs that Undergo Renal Tubular Secretion Clinical Impact When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor for drug-related adverse reactions in patients with renal impairment."
      },
      {
        "interacting_substance": "Examples Acyclovir",
        "severity": "unknown",
        "description": "Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness."
      },
      {
        "interacting_substance": "Management Use",
        "severity": "unknown",
        "description": "Prevention or Management Use additional barrier contraceptive methods."
      }
    ]
  },
  {
    "active_ingredient": "Povidone-Iodine, 10% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid- induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors ( e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin ): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with concurrent use of corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or attenuated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Rugby Cream Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Menthol USP 6%",
    "parsed_interactions": [
      {
        "interacting_substance": "Lidocaine",
        "severity": "moderate",
        "description": "Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Local Anesthetics",
        "severity": "unknown",
        "description": "When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered."
      }
    ]
  },
  {
    "active_ingredient": "(% w/w) Lidocaine 3.88% Menthol 3%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Active ingredient[s] Purpose Isopropyl alcohol 70%v/vâ€¦â€¦.â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦â€¦..................Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "Back Label NDC",
        "severity": "unknown",
        "description": "Back Label NDC 79206-003-06 drug interaction 79206-003-06"
      }
    ]
  },
  {
    "active_ingredient": "Enter section text here",
    "parsed_interactions": [
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic blockers, clonidine, guanethidine, and reserpine."
      }
    ]
  },
  {
    "active_ingredient": "Active Ingredient: Lidocaine 9.6%",
    "parsed_interactions": [
      {
        "interacting_substance": "Reports",
        "severity": "unknown",
        "description": "Reports of interactions have been associated generally with systemic administration of lidocaine which results in high blood concentrations."
      },
      {
        "interacting_substance": "INTERACTIONS Interaction",
        "severity": "unknown",
        "description": "The systemic uptake of lidocaine from SANOBA is unlikely to be sufficient to produce interactions."
      },
      {
        "interacting_substance": "Interactions",
        "severity": "unknown",
        "description": "Interactions have been reported with antiarrhythmic agents, anticonvulsants, anticholinergic agents, antihypertensives, barbiturates, beta-blockers, muscle relaxants and sympathomimetic agents."
      },
      {
        "interacting_substance": "Interactions",
        "severity": "unknown",
        "description": "Interactions with diagnostic tests for serum enzymes have also been reported."
      }
    ]
  },
  {
    "active_ingredient": "Allium cepa 5C, Ambrosia artemisiaefolia 5C, Histaminum hydrochloricum 9C, Euphrasia officinalis 5C, Sabadilla 5C, Soldigo virgaurea 5C",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non drowsy, no drug interactions"
      }
    ]
  },
  {
    "active_ingredient": "Menthol 0.44% Zinc Oxide 20.6%",
    "parsed_interactions": [
      {
        "interacting_substance": "Particular",
        "severity": "moderate",
        "description": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "It also is advisable to \"rest\" a patient's skin until the effects of such preparations subside before use of tretinoin is begun."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Acetaminophen 500 mg",
    "parsed_interactions": [
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin When ibuprofen tablets are administered with aspirin, its protein binding is reduced, although the clearance of free ibuprofen tablets is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ibuprofen and aspirin is not generally recommended because of the potential for increased adverse effects."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Diuretics Clinical studies, as well as post marketing observations, have shown that ibuprofen tablets can reduce the natriuretic effect-of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "(Read circulars for lithium preparation before use of such concurrent therapy.) Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Warfarin-type anticoagulants Several short-term controlled studies failed to show that ibuprofen tablets significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "unknown",
        "description": "However, because bleeding has been reported when ibuprofen tablets and other NSAIDs have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen tablets to patients on anticoagulants."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "H-2 Antagonists In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations."
      }
    ]
  },
  {
    "active_ingredient": "Calendula officinalis 1X",
    "parsed_interactions": [
      {
        "interacting_substance": "Moisturizing",
        "severity": "unknown",
        "description": "Moisturizing - Paraben Free - Ideal for soothing Large areas - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Magnesium citrate 1.745g per fl oz | Active ingredient(s) Bisacodyl 5mg | Purpose White Petrolatum USP (76%) Skin Protectant | Polyethylene Glycol 3350, 17 g (cap filled to line)",
    "parsed_interactions": [
      {
        "interacting_substance": "Additive",
        "severity": "unknown",
        "description": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxidase inhibitors."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine)."
      },
      {
        "interacting_substance": "Gastroparesis",
        "severity": "unknown",
        "description": "Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients."
      },
      {
        "interacting_substance": "Exogenously",
        "severity": "unknown",
        "description": "Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment."
      }
    ]
  },
  {
    "active_ingredient": "-------------------- Betadine Â® Antiseptic/ Povidone-Iodine Swabsticks -------------------- Purpose Povidone Iodine 10% v/v Antiseptic | Drug Facts Purpose Povidone-iodine Solution USP, 10% (equal to 1% available iodine)",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "-------------------- Betadine Â® Antiseptic/ Povidone-Iodine Swabsticks -------------------- Purpose Povidone Iodine 10% v/v Antiseptic | Drug Facts Purpose Povidone-iodine Solution USP, 10% (equal to 1% available iodine)",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "DRUG FACTS in each capsule Acetaminophen 250mg Phenylepherine Hydrochloride 5mg Chlorpheniramide Maleate 2mg Dextromethorphan Hydrobromide 10mg",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug",
        "severity": "moderate",
        "description": "Drug unteraction precautions do not use if you are taking a prescription monoamine oxidase ihibitor (MAOI) (certain drug for depression, psychoatric or emotional conditions, or parkinson's disease), or for 2 weeks after stopping the MAOI drug."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If you do not know if your presctiption drug contains an MAOI, ask a doctor or pharmacist before taking this product."
      }
    ]
  },
  {
    "active_ingredient": "Active ingredient[s] Purpose Isopropyl alcohol 70%v/vâ€¦â€¦.â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦â€¦..................Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "Back Label NDC",
        "severity": "unknown",
        "description": "Back Label NDC 79206-002-02 Back Label NDC 79206-002-02"
      },
      {
        "interacting_substance": "Back Label NDC",
        "severity": "unknown",
        "description": "Back Label NDC 79206-001-05 Back Label NDC 79206-001-05"
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium delayed-release with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium delayed-release and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas coadministration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics ) ."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 10 gr. (650 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "unknown",
        "description": "Ask a physician or pharmacist before use if you are presently taking a prescription drug."
      },
      {
        "interacting_substance": "Antacids",
        "severity": "unknown",
        "description": "Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "Meclizine Hydrochloride, USP 25 mg",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "(see WARNINGS ) Based on in vitro evaluation, Meclizine Hydrochloride, USP is metabolized by CYP2D6."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Therefore there is a possibility for a drug interaction between Meclizine Hydrochloride, USP and CYP2D6 inhibitors."
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 2% w/v Isopropyl alcohol 70% v/v | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "(each inhalant) Ammonia (15%) | Povidone-Iodine, 10% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Infections",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Infections",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%) Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.12) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)"
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Dimethicone 5.0%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS No drug-drug interaction studies have been conducted with mometasone furoate cream 0.1%."
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 2% w/v Isopropyl alcohol 70% v/v | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium delayed-release with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium delayed-release and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas coadministration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics ) ."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Menthol 4% | Lidocaine 4%",
    "parsed_interactions": [
      {
        "interacting_substance": "MAO",
        "severity": "unknown",
        "description": "Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see WARNINGS )."
      },
      {
        "interacting_substance": "Cyclobenzaprine",
        "severity": "minor",
        "description": "Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and other CNS depressants."
      },
      {
        "interacting_substance": "Tricyclic",
        "severity": "unknown",
        "description": "Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds."
      },
      {
        "interacting_substance": "Tricyclic",
        "severity": "minor",
        "description": "Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of cardiac arrhythmias [ see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ]."
      },
      {
        "interacting_substance": "Administer",
        "severity": "unknown",
        "description": "Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in arrhythmias."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot",
        "severity": "unknown",
        "description": "Ergot alkaloids may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "unknown",
        "description": "Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure."
      },
      {
        "interacting_substance": "Sympathomimetic agents",
        "severity": "unknown",
        "description": "possible additive effects ( 7 )"
      },
      {
        "interacting_substance": "Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias ( 7 )"
      },
      {
        "interacting_substance": "Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine ( 7 ) Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine ( 7 ) Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine ( 7 ) Ergot alkaloids may reverse the pressor response to epinephrine ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Ingredients: Each oral tablet provides: Nicotinamide, USP 750 mg Zinc Oxide, USP 25 mg Cupric Oxide 1.5 mg Folic Acid, USP 500 mcg",
    "parsed_interactions": [
      {
        "interacting_substance": "Nicotinamide",
        "severity": "unknown",
        "description": "The clearance of primidone and carbamazepine may be reduced with the concomitant use of Nicotinamide."
      },
      {
        "interacting_substance": "Zinc Oxide",
        "severity": "unknown",
        "description": "The absorption of quinolones or tetracycline may be decreased with the concomitant use of zinc."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use of penicillamines and copper can cause decreased absorption of both substances."
      },
      {
        "interacting_substance": "Large",
        "severity": "unknown",
        "description": "Large doses of Nicotinamide, zinc or copper should be avoided in pregnancy."
      },
      {
        "interacting_substance": "Caution",
        "severity": "moderate",
        "description": "Caution should be exercised when using Nicotinamide, Zinc Oxide, Cupric Acid, Folic Acid Tablets in nursing mothers."
      },
      {
        "interacting_substance": "Safety",
        "severity": "unknown",
        "description": "Safety and effectiveness of Nicotinamide, Zinc Oxide, Cupric Acid, Folic Acid Tablets in pediatric patients have not been established."
      },
      {
        "interacting_substance": "Clinical",
        "severity": "unknown",
        "description": "Clinical studies of Nicotinamide, Zinc Oxide, Cupric Acid, Folic Acid Tablets have not been performed to determine whether elderly subjects respond differently than younger subjects."
      },
      {
        "interacting_substance": "Geriatrics",
        "severity": "unknown",
        "description": "In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."
      },
      {
        "interacting_substance": "Allergic",
        "severity": "unknown",
        "description": "Allergic sensitization has been reported rarely following oral and parenteral administration of Folic Acid."
      },
      {
        "interacting_substance": "Adverse Reactions",
        "severity": "unknown",
        "description": "At recommended doses, Nicotinamide, Zinc Oxide, Cupric Acid, Folic Acid Tablets is expected to be well tolerated."
      },
      {
        "interacting_substance": "Gastrointestinal",
        "severity": "unknown",
        "description": "Gastrointestinal distress such as nausea or vomiting have been associated with the administration of Nicotinamide or zinc at doses greater than the recommended dose."
      },
      {
        "interacting_substance": "Nicotinamide",
        "severity": "unknown",
        "description": "dizziness, headache, hyperglycemia, nausea, vomiting diarrhea, elevations in liver function tests, hepatotoxicity, blurred vision, flushing, rash."
      }
    ]
  },
  {
    "active_ingredient": "Chamomilla 9C, Phytolacca decandra 5C, Rheum 5C",
    "parsed_interactions": [
      {
        "interacting_substance": "Works",
        "severity": "unknown",
        "description": "Works naturally - Safe - No side effects"
      }
    ]
  },
  {
    "active_ingredient": "(in each capsule) Ephedrine Sulfate USP, 25 mg",
    "parsed_interactions": [
      {
        "interacting_substance": "Parkinson",
        "severity": "moderate",
        "description": "Drug Interaction precaution Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinsonâ€™s disease), or for 2 weeks after stopping the MAOI drug."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If you do not know if your prescription drug contains an MAOI, ask a doctor of pharmacist before taking this product."
      }
    ]
  },
  {
    "active_ingredient": "Belladonna 3C, Sanguinaria canadensis 3C, Spigelia anthelmia 3C",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non drowsy, no drug interactions"
      }
    ]
  },
  {
    "active_ingredient": "Each 5 mL (1 teaspoonful) contains Guaifenesin, USP 100 mg and Codeine Phosphate, USP 10 mg. Under federal law, Guaifenesin and Codeine Phosphate Oral Solution USP is available without a prescription. Certain state laws may differ.",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION Caution",
        "severity": "moderate",
        "description": "DRUG INTERACTION PRECAUTION Caution should be used when taking this product with sedatives, tranquilizers and drugs used for depression, especially monoamine oxidase inhibitors (MAOIs)."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These combinations may cause greater sedation (drowsiness) than is caused by the products used alone."
      }
    ]
  },
  {
    "active_ingredient": "Active ingredient(s) Ammonia (15%) | Povidone-Iodine USP 10% w/w (equivalent to 1.0% titratable iodine)",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": ": Methyl Salicylate....30.00% Menthol.................10.00% Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": "LDO Plus",
        "severity": "moderate",
        "description": "LDO Plus should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupiacaine."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases effects of dofetilide thru pharmacodynamic synergism."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs metabolized via CYP3A4 enzyme: (ex."
      },
      {
        "interacting_substance": "Antipsychotics",
        "severity": "minor",
        "description": "Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel bockers, benzodiazopines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that affect hepatic CYP1A2 enzyme: (ex."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Quinoline antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme."
      }
    ]
  },
  {
    "active_ingredient": "Lidocaine HCL 4.00% Menthol 1.00%",
    "parsed_interactions": [
      {
        "interacting_substance": "Only",
        "severity": "unknown",
        "description": "Only at the highest concentration tested (171 mcg/mL; 1 mM) was a slight degree of inhibition (14% to 30%) of isoform CYP2A6 observed."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mcg/mL (approximately 15 times the C max at 3600 mg/day)."
      },
      {
        "interacting_substance": "Gabapentin",
        "severity": "unknown",
        "description": "Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The drug interaction data described in this section were obtained from studies involving healthy adults and adult patients with epilepsy."
      }
    ]
  },
  {
    "active_ingredient": "insulin human (rDNA origin)",
    "parsed_interactions": [
      {
        "interacting_substance": "Adjustment",
        "severity": "unknown",
        "description": "Adjustment of insulin dosage may be needed."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS Drugs that Affect Glucose Metabolism",
        "severity": "unknown",
        "description": "( 7.1 , 7.2 , 7.3 ) Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine) : Signs and symptoms of hypoglycemia may be reduced or absent."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "( 5.3 , 7.4 ) 7.1 Drugs That May Increase the Risk of Hypoglycemia The risk of hypoglycemia associated with HUMULIN N use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide)."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "minor",
        "description": "7.2 Drugs That May Decrease the Blood Glucose Lowering Effect of HUMULIN N The glucose lowering effect of HUMULIN N may be decreased when co-administered with corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "7.3 Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of HUMULIN N The glucose lowering effect of HUMULIN N may be increased or decreased when co-administered with beta-blockers, clonidine, lithium salts, and alcohol."
      },
      {
        "interacting_substance": "Pentamidine",
        "severity": "unknown",
        "description": "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs."
      },
      {
        "interacting_substance": "Symptoms",
        "severity": "moderate",
        "description": "7.4 Drugs That May Blunt Signs and Symptoms of Hypoglycemia The signs and symptoms of hypoglycemia [see Warnings and Precautions ( 5.3 )] may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with HUMULIN N."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (containing capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see WARNINGS AND PRECAUTIONS (5.2) ] Intervention Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS (5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see WARNINGS AND PRECAUTIONS (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%) Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.12) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)"
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Triple Bacitracin zinc 400 units Neomycin sulfate (5 mg equivalent to 3.5 mg Neomycin base) Polymyxin B sulfate 5000 units | BZK Wipe Benzalkonium chloride 0.13% w/v | Eyewash Sterile Water 99% | Hydrocortisone (in each gram) Hydrocortisone acetate (equivalent to Hydrocortisone 1%) | Hand Sanitizer Ethyl alcohol 62% | Alcohol Wipe Isopropyl alcohol 70%",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "17.1 Embryofetal Toxicity Pregnancy loss and malformations Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. Advise that they must use an acceptable form of contraception [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ]. Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate [see Use in Specific Populations (8.1) ]. Contraception Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential [see Use in Specific Populations (8.3) ]. Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence . Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended [see Use in Specific Populations (8.3) ]. For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient. Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ].",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS See full prescribing information (FPI) for drugs that may interfere with systemic exposure and reduce mycophenolate mofetil efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "(7.1) Mycophenolate mofetil may reduce effectiveness of oral contraceptives."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Use of additional barrier contraceptive methods is recommended."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "(7.2) See full prescribing information (FPI) for other important drug interactions."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "unknown",
        "description": "(7) 7.1 Effect of Other Drugs on Mycophenolate Mofetil Table 7: Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration."
      },
      {
        "interacting_substance": "PPIs",
        "severity": "unknown",
        "description": "Proton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Enterohepa",
        "severity": "unknown",
        "description": "Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepa tic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of mycophenolate mofetil related adverse reactions."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Examples Telmisartan",
        "severity": "unknown",
        "description": "Examples Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation)."
      },
      {
        "interacting_substance": "Calcium Free Phosph",
        "severity": "unknown",
        "description": "Calcium Free Phosph ate Binders Clinical Impact Concomitant use with calcium free phosphate binders decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "minor",
        "description": "Examples Sevelamer 7.2 Effect of Mycophenolate Mofetil on Other Drugs Table 8: Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs Drugs that Undergo Renal Tubular Secretion Clinical Impact When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor for drug-related adverse reactions in patients with renal impairment."
      },
      {
        "interacting_substance": "Examples Acyclovir",
        "severity": "unknown",
        "description": "Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness."
      },
      {
        "interacting_substance": "Management Use",
        "severity": "unknown",
        "description": "Prevention or Management Use additional barrier contraceptive methods."
      }
    ]
  },
  {
    "active_ingredient": "Octinoxate 7.5% .................Sunscreen Octisalate 5% .....................Sunscreen Octocrylene 7% ..................Sunscreen Oxybenzone 6% .................Sunscreen Titanium Dioxide 5.7% ........Sunscreen",
    "parsed_interactions": [
      {
        "interacting_substance": "Clindamycin",
        "severity": "minor",
        "description": "Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "moderate",
        "description": "Therefore it should be used with caution in patients receiving such agents."
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.12) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)"
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium injection therapy."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "unknown",
        "description": "anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "If coadministration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions ( 5.1 ) ]."
      },
      {
        "interacting_substance": "Discontinue",
        "severity": "minor",
        "description": "Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium injection or conduct close clinical and laboratory monitoring ( 2.6 , 7 )."
      }
    ]
  },
  {
    "active_ingredient": "17.1 Embryofetal Toxicity Pregnancy loss and malformations Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. Advise that they must use an acceptable form of contraception [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ]. Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate [see Use in Specific Populations (8.1) ]. Contraception Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential [see Use in Specific Populations (8.3) ]. Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence . Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended [see Use in Specific Populations (8.3) ]. For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient. Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ].",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.1) Mycophenolate mofetil may reduce effectiveness of oral contraceptives."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "Use of additional barrier contraceptive methods is recommended."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.2) See FPI for other important drug interactions."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "unknown",
        "description": "(7) 7.1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration."
      },
      {
        "interacting_substance": "PPIs",
        "severity": "unknown",
        "description": "Proton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Enterohepa",
        "severity": "unknown",
        "description": "Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepa tic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Examples Trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of mycophenolate mofetil related adverse reactions."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Examples Telmisartan",
        "severity": "unknown",
        "description": "Examples Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation)."
      },
      {
        "interacting_substance": "Calcium Free Phosph",
        "severity": "unknown",
        "description": "Calcium Free Phosph ate Binders Clinical Impact Concomitant use with calcium free phosphate binders decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "minor",
        "description": "Examples Sevelamer 7.2 Effect of Mycophenolate Mofetil on Other Drugs Table 8 Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs Drugs that Undergo Renal Tubular Secretion Clinical Impact When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor for drug-related adverse reactions in patients with renal impairment."
      },
      {
        "interacting_substance": "Examples Acyclovir",
        "severity": "unknown",
        "description": "Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness."
      },
      {
        "interacting_substance": "Management Use",
        "severity": "unknown",
        "description": "Prevention or Management Use additional barrier contraceptive methods."
      }
    ]
  },
  {
    "active_ingredient": "(per 10 grams) Calcium Carbonate (588 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions Ask a doctor or pharmacist before use If you are presently taking a prescription drug antacids may interact with certain prescriptions drugs."
      }
    ]
  },
  {
    "active_ingredient": "Muscle Rub Menthol 10% Methyl salicylate 15%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions ( 5.11 )]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see Warnings and Precautions ( 5.2 )] Intervention Concomitant use of diclofenac sodium topical solution and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions ( 5.11 )] ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical solution and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6 )] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical solution with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Methotrexate Clinical Impact ; Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical solution and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions ( 5.2 )] ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical solution and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical solution and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives 9 e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium topical solution with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium topical solution and analgesic doses of aspirin is not generally recommended."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Belladonna 3X, Sanguinaria canadensis 3X, Spigelia anthelmia 3X",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non drowsy, no drug interactions"
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (containing capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "section: Guaifenesin, Codeine Phosphate",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION Caution",
        "severity": "moderate",
        "description": "DRUG INTERACTION PRECAUTION Caution should be used when taking this product with sedatives, tranquilizers and drugs used for depression, especially monoamine oxidase inhibitors (MAOIs)."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These combinations may cause greater sedation (drowsiness) than is caused by the products used alone."
      }
    ]
  },
  {
    "active_ingredient": "OTC - SECTION Each 5 mL (1 teaspoonful) contains Guaifenesin, USP 100 mg and Codeine Phosphate, USP 10 mg.",
    "parsed_interactions": [
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These combinations may cause greater sedation (drowsiness) than is caused by the products used alone."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of cardiac arrhythmias [ see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ]."
      },
      {
        "interacting_substance": "Administer",
        "severity": "unknown",
        "description": "Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in arrhythmias."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot",
        "severity": "unknown",
        "description": "Ergot alkaloids may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "unknown",
        "description": "Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure."
      },
      {
        "interacting_substance": "Sympathomimetic agents",
        "severity": "unknown",
        "description": "possible additive effects ( 7 )"
      },
      {
        "interacting_substance": "Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias ( 7 )"
      },
      {
        "interacting_substance": "Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine ( 7 ) Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine ( 7 ) Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine ( 7 ) Ergot alkaloids may reverse the pressor response to epinephrine ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "ACTIVICE Menthol 8.0% | Rugby Cream Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "1.6.6 Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "2.6.9 Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "(In each packet) Calcium Carbonate (4000mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Antacids",
        "severity": "unknown",
        "description": "Antacids may interact with certain prescriptions drugs."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Active ingredient",
    "parsed_interactions": [
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% v/v Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Dynashield -Purpose Zinc Oxide 2% Diaper Rash Dimethicone 1.8% Skin Protectant",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Therefore it should be used with caution in patients receiving such agents."
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin Active Incredients Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding ( see PRECAUTIONS ; Hematological Toxicity )."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding ( see"
      },
      {
        "interacting_substance": "Hematological Toxicity",
        "severity": "unknown",
        "description": "Hematological Toxicity )."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function ( see WARNINGS; Renal Toxicity and Hyperkalemia )."
      },
      {
        "interacting_substance": "These effects are usually reversible Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects ( see WARNINGS; Renal Toxicity and Hyperkalemia )."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy ( see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation )."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers ( see CLINICAL PHARMACOLOGY; Pharmacokinetics )."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol, 70% v/v Purpose Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium topical gel and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium topical gel is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol) In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical gel and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6)]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical gel with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical gel and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical gel and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and Gl toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium topical gel with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium topical gel and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium topical gel may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical gel in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical gel can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics â€‹ Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Salicylic Acid 2.0%",
    "parsed_interactions": [
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "minor",
        "description": "This product contains an alpha-hydroxy acid (AHA) that may increase skin's sensitivity to the sun and particularly thepossibility of sunburn."
      },
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "unknown",
        "description": "Use a sunscreen, wear protective clothing, and limit sun exposure while using this product and for two weeks afterwards."
      }
    ]
  },
  {
    "active_ingredient": "Benzoyl peroxide 2.5% | Octinoxate 7.5% .................Sunscreen Octisalate 5% .....................Sunscreen Octocrylene 7% ..................Sunscreen Oxybenzone 6% .................Sunscreen Titanium Dioxide 5.7% ........Sunscreen",
    "parsed_interactions": [
      {
        "interacting_substance": "Clindamycin",
        "severity": "minor",
        "description": "Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "moderate",
        "description": "Therefore it should be used with caution in patients receiving such agents."
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 2% w/v Isopropyl alcohol 70% v/v | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs) : Monitor patients for bleeding who are concomitantly taking Meloxicam with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of Meloxicam and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-"
      },
      {
        "interacting_substance": "Meloxicam",
        "severity": "minor",
        "description": "Concomitant use with Meloxicam may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Meloxicam",
        "severity": "unknown",
        "description": "Concomitant use with Meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "major",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) See Table 3 for clinically significant drug interactions with meloxicam."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "See also Warnings and Precautions ( 5.2 , 5.6 , 5.11 ) and Clinical Pharmacology ( 12.3 ) ."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 3"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of Meloxicam with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions ( 5.11 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of Meloxicam and low dose aspirin or analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions ( 5.11 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Meloxicam is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors , Angiotensin Receptor Blockers , or Beta -"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, coadministration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of Meloxicam and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of Meloxicam and ACE inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions ( 5.6 )]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of Meloxicam with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )]."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis [see Clinical Pharmacology ( 12.3 )]."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of Meloxicam and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of Meloxicam and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of Meloxicam and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of Meloxicam and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions ( 5.2 )]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of Meloxicam and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of Meloxicam and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "Patients taking meloxicam should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended."
      }
    ]
  },
  {
    "active_ingredient": "Eyewash Sterile Water 99% | PVP Wipe Povidone-iodine 10% (equivalent to 1% titratable iodine) | PAWS Ethyl alcohol 66.5% | Alcohol Wipe Isopropyl alcohol 70%",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 4% solution | Povidone-Iodine, 10% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions - The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied."
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Arnica Montana 9C, Bellis perennis 5C, Ledum palustre 5C",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - non-drowsy - no side effects"
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Anas barbariae hepatis et cordis extractum 200 CK HPUS | Anas barbariae hepatis et cordis extractum 200 CK HPUS",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "No side effects No drug interactions Non Drowsy"
      }
    ]
  },
  {
    "active_ingredient": "Each 5 mL (1 teaspoonful) contains Guaifenesin, USP 100 mg and Codeine Phosphate, USP 10 mg.",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION Caution",
        "severity": "moderate",
        "description": "DRUG INTERACTION PRECAUTION Caution should be used when taking this product with sedatives, tranquilizers and drugs used for depression, especially monoamine oxidase inhibitors (MAOIs)."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These combinations may cause greater sedation (drowsiness) than is caused by the products used alone."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "(Part 3 of 3) Trixaicin Topical Analgesic Cream Drug facts (in each gram) Capsicum oleoresin (containing capsaicin0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole reduces plasma levels of atazanavir and nelfinavir."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use is not recommended."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole increases plasma levels of saquinavir."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for toxicity and consider dose reduction of saquinavir."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "(7.1) May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, erlotinib, ampicillin esters, digoxin and mycophenolate mofetil)."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Patients treated with omeprazole and digoxin may need to be monitored for increases in digoxin toxicity."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole decreases exposure to the active metabolite of clopidogrel."
      },
      {
        "interacting_substance": "Clopidogrel",
        "severity": "unknown",
        "description": "(7.3, 12.3)"
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole increases systemic exposure of cilostazol and one of its active metabolites."
      },
      {
        "interacting_substance": "Consider",
        "severity": "unknown",
        "description": "Consider dose reduction of cilostazol."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "(7.3) Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): omeprazole can prolong their elimination."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor and determine need for dose adjustments."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "(7.3) Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time."
      },
      {
        "interacting_substance": "Cilostazol",
        "severity": "unknown",
        "description": "(7.3) Combined inhibitor of CYP 2C19 and 3A4 (e.g."
      },
      {
        "interacting_substance": "Cilostazol",
        "severity": "unknown",
        "description": "voriconazole) may raise omeprazole levels."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "minor",
        "description": "Omeprazole may increase serum levels of tacrolimus."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Omeprazole may increase serum levels of methotrexate."
      },
      {
        "interacting_substance": "Antiretroviral Therapy Concomitant",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Interference with Antiretroviral Therapy Concomitant use of atazanavir and nelfinavir with proton pump inhibitors is not recommended."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and may result in a loss of therapeutic effect and the development of drug resistance."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "minor",
        "description": "Co-administration of saquinavir with proton pump inhibitors is expected to increase saquinavir concentrations, which may increase toxicity and require dose reduction."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole has been reported to interact with some antiretroviral drugs."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "The clinical importance and the mechanisms behind these interactions are not always known."
      },
      {
        "interacting_substance": "Increased",
        "severity": "unknown",
        "description": "Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug."
      },
      {
        "interacting_substance": "Other",
        "severity": "unknown",
        "description": "Other possible interaction mechanisms are via CYP2C19."
      },
      {
        "interacting_substance": "Reduced",
        "severity": "unknown",
        "description": "Reduced concentrations of atazanavir and nelfinavir For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole."
      },
      {
        "interacting_substance": "Cmin",
        "severity": "unknown",
        "description": "Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8."
      },
      {
        "interacting_substance": "Cmin",
        "severity": "unknown",
        "description": "Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended."
      },
      {
        "interacting_substance": "Increased",
        "severity": "unknown",
        "description": "Increased concentrations of saquinavir For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported, with an increase in AUC by 82%, in Cmax by 75%, and in Cmin by 106%, following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with omeprazole."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose reduction of saquinavir should be considered from the safety perspective for individual patients."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole."
      },
      {
        "interacting_substance": "Which Gastric",
        "severity": "unknown",
        "description": "7.2 Drugs for Which Gastric pH Can Affect Bioavailability Due to its effects on gastric acid secretion, omeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects)."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Co-administration of digoxin with omeprazole is expected to increase the systemic exposure of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Therefore, patients may need to be monitored when digoxin is taken concomitantly with omeprazole."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH."
      },
      {
        "interacting_substance": "MMF",
        "severity": "unknown",
        "description": "The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "moderate",
        "description": "Use omeprazole with caution in transplant patients receiving MMF [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "7.3 Effects on Hepatic Metabolism/Cytochrome P-450 Pathways Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly."
      },
      {
        "interacting_substance": "Increases",
        "severity": "minor",
        "description": "Increases in INR and prothrombin time may lead to abnormal bleeding and even death."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines)."
      },
      {
        "interacting_substance": "Methotrexate",
        "severity": "unknown",
        "description": "Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment of omeprazole is not normally required."
      },
      {
        "interacting_substance": "Zollinger",
        "severity": "unknown",
        "description": "However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered."
      },
      {
        "interacting_substance": "AUC",
        "severity": "major",
        "description": "When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90%"
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "1.8, 2.6) and 4 times (90%"
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole."
      },
      {
        "interacting_substance": "Omeprazole",
        "severity": "unknown",
        "description": "Omeprazole acts as an inhibitor of CYP2C19."
      },
      {
        "interacting_substance": "AUC",
        "severity": "unknown",
        "description": "Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in cross-over study, increased Cmax and AUC of cilostazol by 18% and 26% respectively."
      },
      {
        "interacting_substance": "AUC",
        "severity": "unknown",
        "description": "Cmax and AUC of one of its active metabolites, 3,4-dihydro-cilostazol, which has 4 to 7 times the activity of cilostazol, were increased by 29% and 69% respectively."
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "Co-administration of cilostazol with omeprazole is expected to increase concentrations of cilostazol and its above mentioned active metabolite."
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "Therefore a dose reduction of cilostazol from 100 mg twice daily to 50 mg twice daily should be considered."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels."
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "In a cross-over study in 12 healthy male subjects, St."
      },
      {
        "interacting_substance": "AUC",
        "severity": "unknown",
        "description": "Johnâ€™s Wort (300 mg three times daily for 14 days), an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively)."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant use of St."
      },
      {
        "interacting_substance": "John",
        "severity": "unknown",
        "description": "Johnâ€™s Wort or rifampin with omeprazole."
      },
      {
        "interacting_substance": "Clopidogrel Omeprazole",
        "severity": "unknown",
        "description": "Clopidogrel Omeprazole is an inhibitor of CYP2C19 enzyme."
      },
      {
        "interacting_substance": "Clopidogrel",
        "severity": "unknown",
        "description": "Clopidogrel is metabolized to its active metabolite in part by CYP2C19."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant administration of omeprazole with clopidogrel."
      },
      {
        "interacting_substance": "CI",
        "severity": "unknown",
        "description": "When using omeprazole, consider use of alternative anti-platelet therapy [see Pharmacokinetics (12.3)]."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel."
      },
      {
        "interacting_substance": "CI",
        "severity": "minor",
        "description": "7.4 Tacrolimus Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus."
      },
      {
        "interacting_substance": "Investigations",
        "severity": "moderate",
        "description": "7.5 Interactions with Investigations of Neuroendocrine Tumors Drug-induced decrease in gastric acidity results in enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors [see Warnings and Precautions (5.10) and Clinical Pharmacology (12)]."
      },
      {
        "interacting_substance": "Clarithromycin Concomitant",
        "severity": "severe",
        "description": "7.6 Combination Therapy with Clarithromycin Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [see Warnings and Precautions in prescribing information for clarithromycin]."
      },
      {
        "interacting_substance": "CI",
        "severity": "contraindicated",
        "description": "Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [see Contraindications in prescribing information for clarithromycin]."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.7 Methotrexate Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "However, no formal drug interaction studies of methotrexate with PPIs have been conducted [see Warnings and Precautions (5.11)]."
      }
    ]
  },
  {
    "active_ingredient": ": buprenorphine HCl and naloxone HCl",
    "parsed_interactions": [
      {
        "interacting_substance": "Inducers Buprenorphine",
        "severity": "minor",
        "description": "7.1 Cytochrome P-450 3A4 (CYP3A4) Inhibitors and Inducers Buprenorphine is metabolized to norbuprenorphine primarily by cytochrome CYP3A4; therefore, potential interactions may occur when buprenorphine and naloxone sublingual tablets are given concurrently with agents that affect CYP3A4 activity."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "unknown",
        "description": "The concomitant use of buprenorphine and naloxone sublingual tablets with CYP3A4 inhibitors (e.g., azole antifungals such as ketoconazole, macrolide antibiotics such as erythromycin, and HIV protease inhibitors) should be monitored and may require dose-reduction of one or both agents."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "The interaction of buprenorphine with CYP3A4 inducers has not been studied; therefore, it is recommended that patients receiving buprenorphine and naloxone sublingual tablets be monitored for signs and symptoms of opioid withdrawal if inducers of CYP3A4 (e.g., efavirenz, phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "7.2 Antiretrovirals Three classes of antiretroviral agents have been evaluated for CYP3A4 interactions with buprenorphine."
      },
      {
        "interacting_substance": "Nucleoside",
        "severity": "unknown",
        "description": "Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4."
      },
      {
        "interacting_substance": "Efavirenz",
        "severity": "unknown",
        "description": "Efavirenz, nevirapine and etravirine are known CYP3A inducers whereas delaviridine is a CYP3A inhibitor."
      },
      {
        "interacting_substance": "Significant",
        "severity": "major",
        "description": "Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamic effects."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "It is recommended that patients who are on chronic buprenorphine treatment have their dose monitored if NNRTIs are added to their treatment regimen."
      },
      {
        "interacting_substance": "CYP",
        "severity": "major",
        "description": "Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine and patients in one study reported increased sedation."
      },
      {
        "interacting_substance": "Symptoms",
        "severity": "unknown",
        "description": "Symptoms of opioid excess have been found in post-marketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly."
      },
      {
        "interacting_substance": "Monitoring",
        "severity": "unknown",
        "description": "Monitoring of patients taking buprenorphine and atazanavir with and without ritonavir is recommended, and dose reduction of buprenorphine may be warranted."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.3 Benzodiazepines There have been a number of post-marketing reports regarding coma and death associated with the concomitant use of buprenorphine and benzodiazepines."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In many, but not all of these cases, buprenorphine was misused by self-injection."
      },
      {
        "interacting_substance": "Preclinical",
        "severity": "unknown",
        "description": "Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists."
      },
      {
        "interacting_substance": "Buprenorphine",
        "severity": "moderate",
        "description": "Buprenorphine and naloxone sublingual tablets should be prescribed with caution to patients taking benzodiazepines or other drugs that act on the CNS, regardless of whether these drugs are taken on the advice of a physician or are being abused/misused."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking buprenorphine and naloxone sublingual tablets, and should also be cautioned to use benzodiazepines concurrently with buprenorphine and naloxone sublingual tablets only as directed by their physician."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
      },
      {
        "interacting_substance": "Discontinue",
        "severity": "unknown",
        "description": "Discontinue buprenorphine and naloxone sublingual tablets if serotonin syndrome is suspected."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 10 gr (650 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "moderate",
        "description": "Drug Interaction Precaution"
      },
      {
        "interacting_substance": "Drug Interaction Precaution Ask",
        "severity": "moderate",
        "description": "Drug Interaction Precaution Ask a physician or pharmacist before use if you are presently taking a prescription drug Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "Menthol 4%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see WARNINGS AND PRECAUTIONS (5.2) ] Intervention Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS(5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Methotrexate Clinical Impact; Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see WARNINGS AND PRECAUTIONS (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in ahigher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing info)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): M onitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Folliculinum 15C HPUS (0.8mg), Natrum muriaticum 12C HPUS (0.8mg), Sepia 12C HPUS (0.8mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - no side effects - no drug interactions - works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts (in each tablet) Sodium bicarbonate 10 gr (650 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Antacids",
        "severity": "unknown",
        "description": "Antacids may interact with certain prescription drugs."
      },
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION",
        "severity": "unknown",
        "description": "If you are presently taking a prescription drug, do not take this product without checking with your physician or other health professional."
      }
    ]
  },
  {
    "active_ingredient": "Lidocaine Hydrochloride 4%",
    "parsed_interactions": [
      {
        "interacting_substance": "CYP",
        "severity": "moderate",
        "description": "7 DRUG INTERACTIONS Potent inhibitors of CYP1A2 should be avoided ( 7.1 ) Potent inhibitors of CYP2D6 may increase duloxetine concentrations ( 7.2 ) Duloxetine is a moderate inhibitor of CYP2D6 ( 7.9 ) Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C max was increased about 2.5-fold, and duloxetine t 1/2 was increased approximately 3-fold."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see Warnings and Precautions ( 5.12 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.2 Inhibitors of CYP2D6 Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions ( 5.12 )] ."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "7.3 Dual Inhibition of CYP1A2 and CYP2D6 Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C max ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07)."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "The total warfarin (protein bound plus free drug) pharmacokinetics (AUC T,ss, C max,ss or t max,ss ) for both R- and S-warfarin were not altered by duloxetine."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "moderate",
        "description": "Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued [see Warnings and Precautions ( 5.5 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.5 Lorazepam Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.6 Temazepam Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.7 Drugs that Affect Gastric Acidity Duloxetine delayed-release capsules have an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In extremely acidic conditions, duloxetine, unprotected by the enteric coating, may undergo hydrolysis to form naphthol."
      },
      {
        "interacting_substance": "Caution",
        "severity": "moderate",
        "description": "Caution is advised in using duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics)."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "minor",
        "description": "Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine."
      },
      {
        "interacting_substance": "However",
        "severity": "major",
        "description": "However, co-administration of duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption [see Warnings and Precautions ( 5.14 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.8 Drugs Metabolized by CYP1A2 In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed."
      },
      {
        "interacting_substance": "Duloxetine",
        "severity": "unknown",
        "description": "Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily)."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "7.9 Drugs Metabolized by CYP2D6 Duloxetine is a moderate inhibitor of CYP2D6."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see Warnings and Precautions ( 5.12 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.10 Drugs Metabolized by CYP2C9 Results of in vitro studies demonstrate that duloxetine does not inhibit activity."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine [see Drug Interactions ( 7.4 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.11 Drugs Metabolized by CYP3A Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.12 Drugs Metabolized by CYP2C19 Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations."
      },
      {
        "interacting_substance": "Inhibition",
        "severity": "unknown",
        "description": "Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed."
      },
      {
        "interacting_substance": "Administration",
        "severity": "moderate",
        "description": "7.13 Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.8 , 2.9 ), Contraindications ( 4 ), and Warnings and Precautions ( 5.4 )] ."
      },
      {
        "interacting_substance": "Administration",
        "severity": "moderate",
        "description": "7.14 Serotonergic Drugs [See Dosage and Administration ( 2.8 , 2.9 ), Contraindications (4), and Warnings and Precautions ( 5.4 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.15 Alcohol When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In the duloxetine clinical trials database, three duloxetine -treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen [see Warnings and Precautions ( 5.2 , 5.12 )] ."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "7.16 CNS Drugs [See Warnings and Precautions ( 5.12 )] ."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "7.17 Drugs Highly Bound to Plasma Protein Because duloxetine is highly bound to plasma protein, administration of duloxetine to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "However, co-administration of duloxetine (60 or 120 mg) with warfarin (2 to 9 mg), a highly protein-bound drug, did not result in significant changes in INR and in the pharmacokinetics of either total S-or total R-warfarin (protein bound plus free drug) [see Drug Interactions ( 7.4 )] ."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol, 70% v/v Purpose Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium topical gel and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium topical gel is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol) In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical gel and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6)]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium topical gel with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical gel and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium topical gel and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium topical gel and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and Gl toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium topical gel with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium topical gel and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium topical gel may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical gel in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium topical gel can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 2% w/v Isopropyl alcohol 70% v/v | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Section Section Text Purpose Povidone Iodine 10% v/v Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (containing capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Intervention Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [see WARNINGS AND PRECAUTIONS (5.2) ] Intervention Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see WARNINGS AND PRECAUTIONS (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see WARNINGS AND PRECAUTIONS (5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDS reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDS have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see WARNINGS AND PRECAUTIONS (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Active Ingredients...................................Purpose Trolamine Salicylate(10%).......................Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium delayed-release with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium delayed-release and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas coadministration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics ) ."
      }
    ]
  },
  {
    "active_ingredient": "Aesculus hippocastanum 1X, Collinsonia canadensis 1X, Hamamelis virginiana 1X",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Antimonium tartaricum 6C Bryonia alba 3C Coccus cacti 3C Drosera rotundifolia 3C Ipecacuanha 3C Pulsatilla 6C Rumex crispus 6C Spongia tosta 3C Sticta pulmonaria 3C",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - Non drowsy - Dye Free - No drug interactions - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Menthol 10%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.11) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of NSAID alone [ see Warnings and Precautions (5.2) ]"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.11) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac Sodium is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [ see Warnings and Precautions (5.6) ] When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of diclofenac sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and cyclosporine, monitor patients for signs or worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Concomitant use of oral NSAIDs with diclofenac sodium has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "7%), urea (20% vs."
      },
      {
        "interacting_substance": "NSAIDs and Salicylates Clinical Impact",
        "severity": "unknown",
        "description": "12%) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicyclates is not recommended."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "minor",
        "description": "Do not use combination therapy with diclofenac sodium and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of Diclofenac Sodium and analgesic doses of aspirin is not generally recommended ( 7 ) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 )"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 )"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 )"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": ": Methyl Salicylate....30.00% Menthol.................10.00% Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": "LDO Plus",
        "severity": "moderate",
        "description": "LDO Plus should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupiacaine."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases effects of dofetilide thru pharmacodynamic synergism."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs metabolized via CYP3A4 enzyme: (ex."
      },
      {
        "interacting_substance": "Antipsychotics",
        "severity": "minor",
        "description": "Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel bockers, benzodiazopines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that affect hepatic CYP1A2 enzyme: (ex."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Quinoline antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme."
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (containing capsaicin 0.025%)",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of cardiac arrhythmias [ see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ]."
      },
      {
        "interacting_substance": "Administer",
        "severity": "unknown",
        "description": "Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in arrhythmias."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot",
        "severity": "unknown",
        "description": "Ergot alkaloids may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "unknown",
        "description": "Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure."
      },
      {
        "interacting_substance": "Sympathomimetic agents",
        "severity": "unknown",
        "description": "possible additive effects ( 7 )"
      },
      {
        "interacting_substance": "Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias ( 7 )"
      },
      {
        "interacting_substance": "Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine ( 7 ) Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine ( 7 ) Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine ( 7 ) Ergot alkaloids may reverse the pressor response to epinephrine ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Menthol 0.44% Zinc Oxide 20.6%",
    "parsed_interactions": [
      {
        "interacting_substance": "Particular",
        "severity": "moderate",
        "description": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "It also is advisable to \"rest\" a patient's skin until the effects of such preparations subside before use of tretinoin is begun."
      }
    ]
  },
  {
    "active_ingredient": "NATURAL Menthol USP 2%",
    "parsed_interactions": [
      {
        "interacting_substance": "Renal Effects",
        "severity": "unknown",
        "description": "Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Naproxen sodium and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "major",
        "description": "No significant interactions have been observed in clinical studies with naproxen and coumarin-type anticoagulants."
      },
      {
        "interacting_substance": "However",
        "severity": "moderate",
        "description": "However, caution is advised since interactions have been seen with other nonsteroidal agents of this class."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "minor",
        "description": "The free fraction of warfarin may increase substantially in some subjects and naproxen interferes with platelet function."
      }
    ]
  },
  {
    "active_ingredient": "Chlorhexidine gluconate 4% solution | Povidone-Iodine, 10% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions - The effect of the concurrent application of Mupirocin Ointment USP, 2% and other drug products has not been studied."
      }
    ]
  },
  {
    "active_ingredient": "Active Ingredients",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium delayed-release with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium delayed-release and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas coadministration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics ) ."
      }
    ]
  },
  {
    "active_ingredient": "Acetaminophen Chlorpheniramine Maleate Dextromethorphan HBr Guaifenesin Phenylephrine HCl",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precautions Do",
        "severity": "moderate",
        "description": "Drug Interaction Precautions Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI)."
      },
      {
        "interacting_substance": "Parkinson",
        "severity": "unknown",
        "description": "(certain drugs for depression, psychiatric or emotional conditions, or Parkinson`s disease), or 2 weeks after stopping the MAOI drug."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If you are uncertain whether your presciption drug contains an MAOI, consult a health professional before taking this product"
      }
    ]
  },
  {
    "active_ingredient": "Active Ingrediets Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "This interaction should be given considerationin patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin When IBU tablets are administered with aspirin, its protein bindingis reduced, although the clearance of free IBU tablets is notaltered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however,as with other NSAIDs, concomitant administration of ibuprofenand aspirin is not generally recommended because of the potential forincreased adverse effects."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Aspirin 325 mg (NSAID) 1 1 nonsteroidal anti-inflammatory drug | (in each 5 mL) Diphenhydramine HCl 12.5 mg",
    "parsed_interactions": [
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "7 DRUG INTERACTIONS Cardiac Glycosides, Diuretics, and Anti-arrhythmics Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.5)] ."
      },
      {
        "interacting_substance": "Antihistamines The",
        "severity": "unknown",
        "description": "Antidepressants, Monoamine Oxidase Inhibitors, Levothyroxine, and Antihistamines The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-Adrenergic Blockers The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": "Alpha",
        "severity": "unknown",
        "description": "Alpha-Adrenergic Blockers The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot Alkaloids Ergot",
        "severity": "unknown",
        "description": "Ergot Alkaloids Ergot alkaloids may also reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Cardiac glycosides or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "( 7 ) Beta-adrenergic blocking drugs: antagonize cardiostimulating and bronchodilating effects of epinephrine."
      },
      {
        "interacting_substance": "Tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "( 7 ) Alpha-adrenergic blocking drugs: antagonize vasoconstricting and hypertensive effects of epinephrine."
      },
      {
        "interacting_substance": "Ergot alkaloids",
        "severity": "unknown",
        "description": "may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Beta",
        "severity": "severe",
        "description": "Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol Sulfate Inhalation Aerosol, but may produce severe bronchospasm in asthmatic patients."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "Therefore, patients with asthma should not normally be treated with beta-blockers."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "moderate",
        "description": "In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "The ECG changes and/or hypokalemia which may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics."
      },
      {
        "interacting_substance": "Albuterol",
        "severity": "unknown",
        "description": "Albuterol-"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear; nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol."
      },
      {
        "interacting_substance": "Albuterol Sulfate Inhalation Aerosol",
        "severity": "moderate",
        "description": "Albuterol Sulfate Inhalation Aerosol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the cardiovascular system may be potentiated."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS Ergotamine",
        "severity": "unknown",
        "description": "increased bioavailability of ergotamine."
      },
      {
        "interacting_substance": "Avoid",
        "severity": "unknown",
        "description": "Avoid concomitant use."
      },
      {
        "interacting_substance": "PATIENT COUNSELING INFORMATION",
        "severity": "unknown",
        "description": "(7.2) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling."
      },
      {
        "interacting_substance": "Revised",
        "severity": "contraindicated",
        "description": "10/2021 7.1 PDE-5-Inhibitors and sGC-Stimulators Nitroglycerin sublingual tablets are contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5)."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates."
      },
      {
        "interacting_substance": "Nitroglycerin",
        "severity": "contraindicated",
        "description": "Nitroglycerin sublingual tablets are contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use can cause hypotension."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended."
      },
      {
        "interacting_substance": "Appropriate",
        "severity": "severe",
        "description": "Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "7.2 Ergotamine Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability."
      },
      {
        "interacting_substance": "Ergotamine",
        "severity": "unknown",
        "description": "Ergotamine is known to precipitate angina pectoris."
      },
      {
        "interacting_substance": "Revised",
        "severity": "unknown",
        "description": "Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% v/v Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Class Example Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine"
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "When diclofenac sodium delayed-release is administered with aspirin, its protein binding is reduced."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac sodium delayed-release may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Caution should be used when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as postmarketing observations, have shown that diclofenac sodium delayed-release can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": "Furosemide",
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Inhibitors or Inducers",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "moderate",
        "description": "Use caution when dosing diclofenac with CYP2C9 inhibitors or inducers; a dosage adjustment may be warranted (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Drug Interactions )."
      }
    ]
  },
  {
    "active_ingredient": "Eyewash Sterile Water 99% | Alcohol Wipe Isopropyl alcohol 70% | PVP Wipes Povidone-iodine 10% (equivalent to 1% titratable iodine) | PAWS Ethyl alcohol 66.5%",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "ACTIVICE Menthol 8.0%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "-------------------- Betadine Â® Antiseptic/ Povidone-Iodine Swabsticks -------------------- Purpose Povidone Iodine 10% v/v Antiseptic | Drug Facts Purpose Povidone-iodine Solution USP, 10% (equal to 1% available iodine)",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "TraumaCare 01 500mg Arnica Montana 1M, TraumaCare 02 500mg Arnica Montana 12C",
    "parsed_interactions": [
      {
        "interacting_substance": "Talwin",
        "severity": "unknown",
        "description": "Do not take together with Talwin tm or Talwin NX tm"
      }
    ]
  },
  {
    "active_ingredient": "-------------------- Betadine Â® Antiseptic/ Povidone-Iodine Swabsticks -------------------- Purpose Povidone Iodine 10% v/v Antiseptic | Drug Facts Purpose Povidone-iodine Solution USP, 10% (equal to 1% available iodine)",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Caffeine USP Anhydrous- 200 mg",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "unknown",
        "description": "Do not take with other caffeine-containing medications"
      }
    ]
  },
  {
    "active_ingredient": ": Methyl Salicylate....30.00% Menthol.................10.00% Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": "LDO Plus",
        "severity": "moderate",
        "description": "LDO Plus should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupiacaine."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases effects of dofetilide thru pharmacodynamic synergism."
      },
      {
        "interacting_substance": "Lidocaine Hydrochloride USP",
        "severity": "unknown",
        "description": "Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs metabolized via CYP3A4 enzyme: (ex."
      },
      {
        "interacting_substance": "Antipsychotics",
        "severity": "minor",
        "description": "Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel bockers, benzodiazopines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that affect hepatic CYP1A2 enzyme: (ex."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Quinoline antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme."
      }
    ]
  },
  {
    "active_ingredient": "OTC - ACTIVE INGREDIENT",
    "parsed_interactions": [
      {
        "interacting_substance": "Adjustment",
        "severity": "unknown",
        "description": "Adjustment of insulin dosage may be needed."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS Drugs that Affect Glucose Metabolism",
        "severity": "unknown",
        "description": "( 7.1 , 7.2 , 7.3 ) Anti-Adrenergic Drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine) : Signs and symptoms of hypoglycemia may be reduced or absent."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "( 5.3 , 7.4 ) The risk of hypoglycemia associated with HUMULIN 70/30 use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide)."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "The glucose lowering effect of HUMULIN 70/30 may be decreased when co-administered with corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The glucose lowering effect of HUMULIN 70/30 may be increased or decreased when co-administered with beta-blockers, clonidine, lithium salts, and alcohol."
      },
      {
        "interacting_substance": "Pentamidine",
        "severity": "unknown",
        "description": "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia."
      },
      {
        "interacting_substance": "Dose",
        "severity": "unknown",
        "description": "Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "The signs and symptoms of hypoglycemia [see Warnings and Precautions ( 5.3 )] may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with HUMULIN 70/30."
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding ( see PRECAUTIONS; Hematological Toxicity)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding ( see"
      },
      {
        "interacting_substance": "Hematological Toxicity",
        "severity": "unknown",
        "description": "Hematological Toxicity)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors , Angiotens in Receptor Blockers , and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function ( see WARNINGS; Renal Toxicity and Hyperkalemia)."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects ( see WARNINGS; Renal Toxicity and Hyperkalemia)."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy ( see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs ): Monitor patients for bleeding who are concomitantly using diclofenac sodium with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of diclofenac sodium and analgesic doses of aspirin is not generally recommended (7) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "minor",
        "description": "Concomitant use with diclofenac sodium may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure (7)"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function (7)"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDS can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects (7)"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with diclofenac sodium can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels (7)"
      }
    ]
  },
  {
    "active_ingredient": "Carbo vegetabilis 5C, Colocynthis 9C, Cuprum metallicum 5C",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - no side effects - works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Benzoyl peroxide 4.4% | Benzoyl peroxide 4.4%",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage."
      },
      {
        "interacting_substance": "Since",
        "severity": "unknown",
        "description": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin."
      },
      {
        "interacting_substance": "Absorption",
        "severity": "unknown",
        "description": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of tetracycline may render oral contraceptives less effective."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of cardiac arrhythmias [ see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ]."
      },
      {
        "interacting_substance": "Administer",
        "severity": "unknown",
        "description": "Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in arrhythmias."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine."
      },
      {
        "interacting_substance": "Ergot",
        "severity": "unknown",
        "description": "Ergot alkaloids may reverse the pressor effects of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "unknown",
        "description": "Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure."
      },
      {
        "interacting_substance": "Sympathomimetic agents",
        "severity": "unknown",
        "description": "possible additive effects ( 7 )"
      },
      {
        "interacting_substance": "Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics",
        "severity": "unknown",
        "description": "observe for development of cardiac arrhythmias ( 7 )"
      },
      {
        "interacting_substance": "Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines",
        "severity": "unknown",
        "description": "potentiate effects of epinephrine ( 7 ) Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine ( 7 ) Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine ( 7 ) Ergot alkaloids may reverse the pressor response to epinephrine ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Drug Facts Benzoyl peroxide 4.4% | Benzoyl peroxide 4.4%",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage."
      },
      {
        "interacting_substance": "Since",
        "severity": "unknown",
        "description": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin."
      },
      {
        "interacting_substance": "Absorption",
        "severity": "unknown",
        "description": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity."
      },
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of tetracycline may render oral contraceptives less effective."
      }
    ]
  },
  {
    "active_ingredient": "(% by weight) Camphor 4% Menthol 10%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Diclofenac sodium (NSAID*) 1% (equivalent to 0.93% diclofenac) *nonsteroidal anti-inflammatory drug",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Following oral administration, leflunomide is metabolized to an active metabolite, teriflunomide, which is responsible for essentially all of leflunomide's in vivo activity."
      },
      {
        "interacting_substance": "Drug",
        "severity": "unknown",
        "description": "Drug interaction studies have been conducted with both leflunomide and with its active metabolite, teriflunomide, where the metabolite was directly administered to the test subjects."
      },
      {
        "interacting_substance": "Effect",
        "severity": "unknown",
        "description": "Effect of potent CYP and transporter inducers Leflunomide is metabolized by CYP450 metabolizing enzymes."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant use of leflunomide tablets and rifampin, a potent inducer of CYP and transporters, increased the plasma concentration of teriflunomide by 40%."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, when co-administered with the metabolite, teriflunomide, rifampin did not affect its pharmacokinetics."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "No dosage adjustment is recommended for leflunomide tablets when coadministered with rifampin."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Because of the potential for leflunomide tablets concentrations to continue to increase with multiple dosing, caution should be used if patients are to be receiving both leflunomide tablets and rifampin [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "Effect",
        "severity": "unknown",
        "description": "Effect on CYP2C8 substrates Teriflunomide is an inhibitor of CYP2C8 in vivo."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In patients taking leflunomide tablets, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "minor",
        "description": "Effect on warfarin Coadministration of leflunomide tablets with warfarin requires close monitoring of the international normalized ratio (INR) because teriflunomide, the active metabolite of leflunomide tablets, may decrease peak INR by approximately 25%."
      },
      {
        "interacting_substance": "Effect",
        "severity": "minor",
        "description": "Effect on oral contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel."
      },
      {
        "interacting_substance": "Consideration",
        "severity": "unknown",
        "description": "Consideration should be given to the type or dose of contraceptives used in combination with leflunomide tablets [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "Effect",
        "severity": "unknown",
        "description": "Effect on CYP1A2 substrates Teriflunomide, the active metabolite of leflunomide tablets, may be a weak inducer of CYP1A2 in vivo."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In patients taking leflunomide tablets, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "Effect",
        "severity": "unknown",
        "description": "Effect on organic anion transporter 3 (OAT3) substrates Teriflunomide inhibits the activity of OAT3 in vivo."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "In patients taking leflunomide tablets, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "OATP",
        "severity": "unknown",
        "description": "Effect on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "For a patient taking leflunomide tablets, the dose of rosuvastatin should not exceed 10 mg once daily."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG- Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking leflunomide tablets [see Clinical Pharmacology (12.3)]."
      },
      {
        "interacting_substance": "OAT",
        "severity": "minor",
        "description": "Drugs metabolized by CYP2C8 and OAT3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "(7) Teriflunomide may increase exposure of ethinylestradiol and levonorgestrel."
      },
      {
        "interacting_substance": "Choose",
        "severity": "unknown",
        "description": "Choose an appropriate oral contraceptive."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "(7) Drugs metabolized by CYP1A2: Monitor patients because teriflunomide may decrease exposure of these drugs."
      },
      {
        "interacting_substance": "INR",
        "severity": "minor",
        "description": "Monitor INR as teriflunomide may decrease INR."
      },
      {
        "interacting_substance": "OATP",
        "severity": "minor",
        "description": "(7) Drugs metabolized by BCRP and OATP1B1/B3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs."
      },
      {
        "interacting_substance": "Rosuvastatin",
        "severity": "unknown",
        "description": "The dose of rosuvastatin should not exceed 10 mg once daily in patients taking leflunomide tablets."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine"
      }
    ]
  },
  {
    "active_ingredient": "Salicylic Acid 2.0%",
    "parsed_interactions": [
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "minor",
        "description": "This product contains an alpha-hydroxy acid (AHA) that may increase skin's sensitivity to the sun and particularly thepossibility of sunburn."
      },
      {
        "interacting_substance": "Sunburn Alert",
        "severity": "unknown",
        "description": "Use a sunscreen, wear protective clothing, and limit sun exposure while using this product and for two weeks afterwards."
      }
    ]
  },
  {
    "active_ingredient": "Acetaminofen Dextromethorphan HBr Phenylephryne HCL Chlorpheniramine Maleate",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI), (Certain drugs for depression, psychiatric or emotional conditions, or Parkinsons disease) or for 2 weeks after stopping that MAOI drug, if you are uncertain whether your prescription drug contains an MAOI, consult a health professional before taking this product"
      }
    ]
  },
  {
    "active_ingredient": "Capsicum Oleoresin 0.0625% (Containing Capsaicin 0.025%) Purpose Topical Analgesic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 1:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of naproxen with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions (5.12) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( see 12.2 Pharmacodynamics )."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Because there may be an increased risk of cardiovascular events following discontinuation of naproxen due to the interference with the antiplatelet effect of aspirin during the washout period, for patients taking low-dose aspirin for cardioprotection who require intermittent analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics where appropriate."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of naproxen and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions (5.12) ]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Naproxen Tablets are not substitutes for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "During concomitant use of naproxen and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of naproxen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of naproxen and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [ see Warnings and Precautions (5.2) ]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of naproxen with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of naproxen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of naproxen and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 mL/min to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "unknown",
        "description": "Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen is not recommended."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "unknown",
        "description": "Concomitant administration of cholestyramine can delay the absorption of naproxen."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "unknown",
        "description": "Concomitant administration of cholestyramine with naproxen is not recommended."
      },
      {
        "interacting_substance": "Probenecid",
        "severity": "major",
        "description": "Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "Patients simultaneously receiving naproxen and probenecid should be observed for adjustment of dose if required."
      },
      {
        "interacting_substance": "Other",
        "severity": "unknown",
        "description": "Other albumin-bound drugs"
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "Patients simultaneously receiving naproxen and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required."
      },
      {
        "interacting_substance": "Drug",
        "severity": "unknown",
        "description": "Drug/"
      },
      {
        "interacting_substance": "Naproxen",
        "severity": "minor",
        "description": "Naproxen may decrease platelet aggregation and prolong bleeding time."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "This effect should be kept in mind when bleeding times are determined."
      },
      {
        "interacting_substance": "Porter",
        "severity": "unknown",
        "description": "Porter-"
      },
      {
        "interacting_substance": "Silber test Clinical Impact",
        "severity": "unknown",
        "description": "The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay."
      },
      {
        "interacting_substance": "Although",
        "severity": "unknown",
        "description": "Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used."
      },
      {
        "interacting_substance": "Urinary",
        "severity": "unknown",
        "description": "Urinary assays of 5-hydroxy indoleacetic acid (5HIAA)"
      },
      {
        "interacting_substance": "Naproxen",
        "severity": "unknown",
        "description": "Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA)."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "This effect should be kept in mind when urinary 5-hydroxy indoleacetic acid is determined."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs) : Monitor patients for bleeding who are concomitantly taking Naproxen Tablets with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of Naproxen Tablets and analgesic doses of aspirin is not generally recommended."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "(7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "Naproxen Tablets",
        "severity": "minor",
        "description": "Concomitant use with Naproxen Tablets may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure."
      },
      {
        "interacting_substance": "Naproxen Tablets",
        "severity": "unknown",
        "description": "Concomitant use with Naproxen Tablets in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with Naproxen Tablets can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels."
      }
    ]
  },
  {
    "active_ingredient": "Cetrimide",
    "parsed_interactions": [
      {
        "interacting_substance": "Interactions The",
        "severity": "unknown",
        "description": "Interactions The product is incompatible with anionic substances (e.g."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "CYP 3A4 inhibitors: Triamcinolone acetonide is a substrate of CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Cyclosporine",
        "severity": "unknown",
        "description": "Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with triamcinolone acetonide injectable suspension may cause increased plasma concentration of triamcinolone leading to adverse reactions (see ADVERSE REACTIONS )."
      },
      {
        "interacting_substance": "PRECAUTIONS",
        "severity": "major",
        "description": "During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving triamcinolone acetonide and strong CYP3A4 inhibitors (e.g., ritonavir) (see WARNINGS, Endocrine and PRECAUTIONS, Endocrine )."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit-risk of concomitant use and monitor for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Estrogens, including oral contraceptives",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Lidocaine Hydrochloride 3% Purpose: Anesthetic",
    "parsed_interactions": [
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, inepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, paraÂ¬aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine"
      }
    ]
  },
  {
    "active_ingredient": "Ingredients Strength Acetylcysteine 200 mg Methyltetrahydrofolate(Vitamin B9) 2.5 mg Methylcobalamin (Vitamin B12) 2.5 mg Pyridoxal 5'-phosphate (Vitamin B6) 20 mg Nicotinamide (Vitamin B3) 10 mg Cholecalciferol (Vitamin D3) 1000 IU Chromium Picolinate 1 mg Alpha Lipoic Acid 200 mg Coenzyme Q10 16 mg Resveratrol 83 mg",
    "parsed_interactions": [
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, pyridoxine hydrochloride may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "â€¢ High dose folic acid may result in decreased serum levels for pyrimethamine and first-generation anticonvulsants (carbamazepine, fosphenytoin, phenytoin, phenobarbital, primidone, valproic acid, valproate)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "â€¢ Folic acid may decrease a patient's response to methotrexate."
      },
      {
        "interacting_substance": "Drug interactions with folate",
        "severity": "minor",
        "description": "â€¢ 5-formyltetrahydrofolate may increase the toxicity of Capecitabine."
      },
      {
        "interacting_substance": "Drug interactions with folate",
        "severity": "unknown",
        "description": "â€¢ Nitrous oxide can produce a functional vitamin B12 deficiency."
      }
    ]
  },
  {
    "active_ingredient": "(% w/w) Avobenzone 2.5% Octinoxate 3% Octisalate 3% Titanium Dioxide 1.25%",
    "parsed_interactions": [
      {
        "interacting_substance": "Particular",
        "severity": "moderate",
        "description": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin cream."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "It also is advisable to â€œrestâ€ a patientâ€™s skin until the effects of such preparations subside before use of tretinoin cream is begun."
      }
    ]
  },
  {
    "active_ingredient": "Borax 14X, Calendula officinalis 1X, Candida Albicans 30X, Hydrastis canadensis 1X",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Formula: Each tablet contains Acetylsalicylic acid 0.500 g Anhydrous caffeine 0.065 g Excipient cbp 1 tablet effervescent",
    "parsed_interactions": [
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Not to be administered concurrently with anticoagulants, corticosteroids, anti-rheumatic, sulfonylureas, methotrexate, alcohol and antidrip drugs."
      }
    ]
  },
  {
    "active_ingredient": "Aconitum napellus 6C, Belladona 6C, Calendula officinalis 6C, Chelidonium majus 6C, Jequirity 6C, Viburnum opulus 6C",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non habit forming, no drug interactions"
      }
    ]
  },
  {
    "active_ingredient": "Arnica montana 3C, Arum triphyllum 3C, Belladonna 3C, Bromium 3C, Bryonia alba 3C, Mercuris solubilis 3C, Pulsatilla 3C, Phytolacca decandra 3C, Spongia tosta 3C",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non drowsy, no drug interactions"
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding ( see PRECAUTIONS; Hematological Toxicity)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding ( see"
      },
      {
        "interacting_substance": "Hematological Toxicity",
        "severity": "unknown",
        "description": "Hematological Toxicity)."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors , Angiotens in Receptor Blockers , and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function ( see WARNINGS; Renal Toxicity and Hyperkalemia)."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects ( see WARNINGS; Renal Toxicity and Hyperkalemia)."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy ( see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers ( see CLINICAL PHARMACOLOGY; Pharmacokinetics)."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol, 70% v/v Purpose Antiseptic",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "major",
        "description": "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac."
      },
      {
        "interacting_substance": "Table",
        "severity": "unknown",
        "description": "Table 2:"
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "â€¢ Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact",
        "severity": "unknown",
        "description": "â€¢ S er otonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of VOLTAREN Â® GEL with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions ( 5.11 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of VOLTAREN Â® GEL and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions ( 5.11 )]."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "VOLTAREN Â® GEL is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "â€¢ NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "â€¢ In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "â€¢ During concomitant use of VOLTAREN Â® GEL and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "moderate",
        "description": "â€¢ During concomitant use of VOLTAREN Â® GEL and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions ( 5.6 )]."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "â€¢When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter ."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "moderate",
        "description": "During concomitant use of VOLTAREN Â® GEL with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 )]."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of VOLTAREN Â® GEL and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of VOLTAREN Â® GEL and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of VOLTAREN Â® GEL and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of VOLTAREN Â® GEL and cyclosporine may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of VOLTAREN Â® GEL and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions ( 5.2 )]."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is notrecommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of VOLTAREN Â® GEL and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of VOLTAREN Â® GEL and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and Gl toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Hemostasis",
        "severity": "unknown",
        "description": "â€¢ Drugs that Interfere with Hemostasis (e.g."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "warfarin, aspirin, SSRIs/SNRIs) : Monitor patients for bleeding who are concomitantly using VOLTAREN Â® GEL with drugs that interfere with hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Concomitant use of VOLTAREN Â® GEL and analgesic doses of aspirin is not generally recommended ( 7 ) â€¢ ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-"
      },
      {
        "interacting_substance": "VOLTAREN",
        "severity": "minor",
        "description": "Concomitant use with VOLTAREN Â® GEL may diminish the antihypertensive effect of these drugs."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor blood pressure ( 7 ) â€¢"
      },
      {
        "interacting_substance": "VOLTAREN",
        "severity": "unknown",
        "description": "Concomitant use with VOLTAREN Â® GEL in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function."
      },
      {
        "interacting_substance": "ACE Inhibitors and ARBs",
        "severity": "minor",
        "description": "In such high risk patients, monitor for signs of worsening renal function ( 7 ) â€¢"
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) â€¢"
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Concomitant use with VOLTAREN Â® GEL can increase serum concentration and prolong half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Monitor serum digoxin levels ( 7 )"
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Buprenorphine",
        "severity": "unknown",
        "description": "Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The barbiturate methohexital appears to block the acute onset of withdrawal symptoms induced by naloxone in opiate addicts."
      }
    ]
  },
  {
    "active_ingredient": "(% w/w) Lidocaine 5% Menthol 3%",
    "parsed_interactions": [
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism."
      },
      {
        "interacting_substance": "Potent",
        "severity": "unknown",
        "description": "Potent inhibitors of CYP1A2 should be avoided ( 7.1 )."
      },
      {
        "interacting_substance": "Potent",
        "severity": "minor",
        "description": "Potent inhibitors of CYP2D6 may increase duloxetine concentrations ( 7.2 )."
      },
      {
        "interacting_substance": "Duloxetine",
        "severity": "moderate",
        "description": "Duloxetine is a moderate inhibitor of CYP2D6 ( 7.9 )."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was coadministered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C max was increased about 2.5-fold, and duloxetine t 1/2 was increased approximately 3-fold."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.2 Inhibitors of CYP2D6 Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "7.3 Dual Inhibition of CYP1A2 and CYP2D6 Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C max ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministered with warfarin."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07)."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "The total warfarin (protein bound plus free drug) pharmacokinetics (AUC Ï„,ss , C max,ss or t max,ss ) for both R- and S-warfarin were not altered by duloxetine."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "moderate",
        "description": "Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued [see Warnings and Precautions (5.5) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.5 Lorazepam Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by coadministration."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.6 Temazepam Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by coadministration."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.7 Drugs that Affect Gastric Acidity Duloxetine delayed-release has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In extremely acidic conditions, duloxetine delayed-release, unprotected by the enteric coating, may undergo hydrolysis to form naphthol."
      },
      {
        "interacting_substance": "Caution",
        "severity": "moderate",
        "description": "Caution is advised in using duloxetine delayed-release in patients with conditions that may slow gastric emptying (e.g., some diabetics)."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "minor",
        "description": "Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine."
      },
      {
        "interacting_substance": "However",
        "severity": "major",
        "description": "However, coadministration of duloxetine delayed-release with aluminum- and magnesium-containing antacids (51 mEq) or duloxetine delayed-release with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption [see Warnings and Precautions (5.14) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.8 Drugs Metabolized by CYP1A2 In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed."
      },
      {
        "interacting_substance": "Duloxetine",
        "severity": "unknown",
        "description": "Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when coadministered with duloxetine (60 mg twice daily)."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "7.9 Drugs Metabolized by CYP2D6 Duloxetine is a moderate inhibitor of CYP2D6."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.10 Drugs Metabolized by CYP2C9 Results of in vitro studies demonstrate that duloxetine does not inhibit activity."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine [see Drug Interactions (7.4) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.11 Drugs Metabolized by CYP3A Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.12 Drugs Metabolized by CYP2C19 Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations."
      },
      {
        "interacting_substance": "Inhibition",
        "severity": "unknown",
        "description": "Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed."
      },
      {
        "interacting_substance": "Administration",
        "severity": "moderate",
        "description": "7.13 Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration (2.5 , 2.6) , Contraindications (4.1) , and Warnings and Precautions (5.4) ] ."
      },
      {
        "interacting_substance": "Administration",
        "severity": "moderate",
        "description": "7.14 Serotonergic Drugs [See Dosage and Administration (2.5 , 2.6) , Contraindications (4.1) , and Warnings and Precautions (5.4) ]."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.15 Alcohol When duloxetine delayed-release and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine delayed-release did not increase the impairment of mental and motor skills caused by alcohol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In the duloxetine delayed-release clinical trials database, three duloxetine delayed-release-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen [see Warnings and Precautions (5.2 and 5.12) ] ."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "7.16 CNS Drugs [See Warnings and Precautions (5.12) ] ."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "7.17 Drugs Highly Bound to Plasma Protein Because duloxetine is highly bound to plasma protein, administration of duloxetine delayed-release to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "However, coadministration of duloxetine (60 or 120 mg) with warfarin (2 to 9 mg), a highly protein-bound drug, did not result in significant changes in INR and in the pharmacokinetics of either total S-or total R-warfarin (protein bound plus free drug) [see Drug Interactions (7.4) ] ."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 5 gr (325 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "moderate",
        "description": "Drug Interaction Precaution"
      },
      {
        "interacting_substance": "Drug Interaction Precaution Ask",
        "severity": "moderate",
        "description": "Drug Interaction Precaution Ask a physician or pharmacist before use if you are presently taking a prescription drug Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "Triple Bacitracin zinc 400 units Neomycin sulfate (5 mg equivalent to 3.5 mg Neomycin base) Polymyxin B sulfate 5000 units | BZK Wipe Benzalkonium chloride 0.13% w/v | Eyewash Sterile Water 99% | Hydrocortisone (in each gram) Hydrocortisone acetate (equivalent to Hydrocortisone 1%) | Hand Sanitizer Ethyl alcohol 62% | Alcohol Wipe Isopropyl alcohol 70% | Ammonia Inhalent Ammonia 15%",
    "parsed_interactions": [
      {
        "interacting_substance": "Consult",
        "severity": "unknown",
        "description": "Consult with pharmacist.When introducing additives, use aseptic technique.Mix thoroughly."
      }
    ]
  },
  {
    "active_ingredient": "Guaifenesin Dextromethorphan HBr",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Id you are uncertain ehether your prescription drug contains an MAOI, consult a health professional before taking this product"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Active ingredient",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering OMNIPAQUE to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Drugs",
        "severity": "unknown",
        "description": "Drugs that Lower Seizure Threshold Drugs that lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with intrathecal administration of OMNIPAQUE."
      },
      {
        "interacting_substance": "CNS Active Drugs Drugs",
        "severity": "major",
        "description": "CNS Active Drugs Drugs such as monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs."
      },
      {
        "interacting_substance": "Such",
        "severity": "unknown",
        "description": "Such medications should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours post procedure."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In non-elective procedures in patients on these drugs, consider prophylactic use of anticonvulsants."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests If iodine-containing isotopes are to be administered for the diagnosis of thyroid disease, the iodine-binding capacity of thyroid tissue may be reduced for up to 2 weeks after contrast medium administration."
      },
      {
        "interacting_substance": "Thyroid",
        "severity": "unknown",
        "description": "Thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Methyl Salicylate 25.00% Menthol 6.00% Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Ketorolac does not alter digoxin protein binding."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "minor",
        "description": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential two-fold increase in unbound ketorolac plasma levels."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Therapeutic concentrations of digoxi n , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac tromethamine protein binding."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "In a study involving 12 adult volunteers, oral ketorolac tromethamine was coadministered with a single dose of 25 mg warfarin , causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "In another study, ketorolac tromethamine dosed intravenous or intramuscular was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see WARNINGS and PRECAUTIONS â€“ Hematologic Effects )."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "The effects of warfarin and NSAIDs, in general, on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than the users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin When ketorolac tromethamine is administered with aspirin, its protein binding is reduced, although the clearance of free ketorolac tromethamine is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ketorolac tromethamine and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Diuretics Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS â€“ Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "Probenecid Concomitant",
        "severity": "major",
        "description": "Probenecid Concomitant administration of oral ketorolac tromethamine and probenecid resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately three-fold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately two-fold from 6.6 to 15.1 hours."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "contraindicated",
        "description": "Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "Antagonists Concomitant",
        "severity": "minor",
        "description": "ACE Inhibitors/Angiotensin II Receptor Antagonists Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine)."
      },
      {
        "interacting_substance": "Psychoactive Drugs Hallucinations",
        "severity": "unknown",
        "description": "Psychoactive Drugs Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam)."
      },
      {
        "interacting_substance": "Pentoxifylline When",
        "severity": "unknown",
        "description": "Pentoxifylline When ketorolac tromethamine is administered concurrently with pentoxifylline , there is an increased tendency to bleeding."
      },
      {
        "interacting_substance": "Nondepolarizing Muscle Relaxants In",
        "severity": "unknown",
        "description": "Nondepolarizing Muscle Relaxants In postmarketing experience there have been reports of a possible interaction between ketorolac tromethamine intravenous/intramuscular and nondepolarizing muscle relaxants that resulted in apnea."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Selective Serotonin Reuptake Inhibitors (SSRIs) There is an increased risk of gastrointestinal bleeding when selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with SSRIs."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Active ingredient",
    "parsed_interactions": [
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "Ketorolac does not alter digoxin protein binding."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential two-fold increase in unbound ketorolac plasma levels."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Therapeutic concentrations of digoxi n , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac tromethamine protein binding."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "In a study involving 12 adult volunteers, oral ketorolac tromethamine was coadministered with a single dose of 25 mg warfarin , causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In another study, ketorolac tromethamine dosed intravenous or intramuscular was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "major",
        "description": "Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see WARNINGS and PRECAUTIONS â€“ Hematologic Effects )."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "The effects of warfarin and NSAIDs, in general, on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than the users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin When ketorolac tromethamine is administered with aspirin, its protein binding is reduced, although the clearance of free ketorolac tromethamine is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ketorolac tromethamine and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Diuretics Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "This response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS â€“ Renal Effects ), as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "Probenecid Concomitant",
        "severity": "major",
        "description": "Probenecid Concomitant administration of oral ketorolac tromethamine and probenecid resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately three-fold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately two-fold from 6.6 to 15.1 hours."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "Antagonists Concomitant",
        "severity": "minor",
        "description": "ACE Inhibitors/Angiotensin II Receptor Antagonists Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine)."
      },
      {
        "interacting_substance": "Psychoactive Drugs Hallucinations",
        "severity": "unknown",
        "description": "Psychoactive Drugs Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam)."
      },
      {
        "interacting_substance": "Pentoxifylline When",
        "severity": "unknown",
        "description": "Pentoxifylline When ketorolac tromethamine is administered concurrently with pentoxifylline , there is an increased tendency to bleeding."
      },
      {
        "interacting_substance": "Nondepolarizing Muscle Relaxants In",
        "severity": "unknown",
        "description": "Nondepolarizing Muscle Relaxants In postmarketing experience there have been reports of a possible interaction between ketorolac tromethamine intravenous/intramuscular and nondepolarizing muscle relaxants that resulted in apnea."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Selective Serotonin Reuptake Inhibitors (SSRIs) There is an increased risk of gastrointestinal bleeding when selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "Caution should be used when NSAIDs are administered concomitantly with SSRIs."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6, 7.2) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6, 7.3) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6, 7.4)"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13, 7.6) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "There",
        "severity": "unknown",
        "description": "There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Menthol 6%",
    "parsed_interactions": [
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Examples of Drugs Associated with Methemoglobinemia Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine"
      }
    ]
  },
  {
    "active_ingredient": "Dimethicone 5.0%",
    "parsed_interactions": [
      {
        "interacting_substance": "Lidocaine",
        "severity": "moderate",
        "description": "Lidocaine patch 5% should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic."
      },
      {
        "interacting_substance": "Local Anesthetics",
        "severity": "unknown",
        "description": "When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered."
      }
    ]
  },
  {
    "active_ingredient": "Povidone Iodine 10% v/v (equivalent to 1% titratable iodine) | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Vaccination",
        "severity": "unknown",
        "description": "Vaccination )."
      }
    ]
  },
  {
    "active_ingredient": "Benzalkonium Chloride, 0.13% w/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Except",
        "severity": "contraindicated",
        "description": "Except in life-threatening situations, avoid this combination."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "severe",
        "description": "Furosemide combined with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "An interruption or reduction in the dosage of furosemide, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers may be necessary."
      },
      {
        "interacting_substance": "Potentiation",
        "severity": "unknown",
        "description": "Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide may decrease arterial responsiveness to norepinephrine."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, norepinephrine may still be used effectively."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "The intake of furosemide and sucralfate should be separated by at least two hours."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Use of furosemide concomitantly with chloral hydrate is therefore not recommended."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Phenytoin interferes directly with renal action of furosemide."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "There is evidence that treatment with phenytoin leads to decreased intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "major",
        "description": "Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Literature reports indicate that co-administration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis."
      },
      {
        "interacting_substance": "Indomethacin",
        "severity": "unknown",
        "description": "Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved."
      }
    ]
  },
  {
    "active_ingredient": "Dimethicone (Blend) 92%",
    "parsed_interactions": [
      {
        "interacting_substance": "Interactions Delice",
        "severity": "unknown",
        "description": "Interactions Delice Â® could react with certain hair care and hair tinting products."
      }
    ]
  },
  {
    "active_ingredient": "Capsaicin 0.025%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "1.6.5 Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "contraindicated",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      }
    ]
  },
  {
    "active_ingredient": "Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "contraindicated",
        "description": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "Clinically Significant Drug Interactions",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "section: Guaifenesin, Codeine Phosphate",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTION PRECAUTION Caution",
        "severity": "moderate",
        "description": "DRUG INTERACTION PRECAUTION Caution should be used when taking this product with sedatives, tranquilizers and drugs used for depression, especially monoamine oxidase inhibitors (MAOIs)."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These combinations may cause greater sedation (drowsiness) than is caused by the products used alone."
      }
    ]
  },
  {
    "active_ingredient": "SinEcch 01 500mg Arnica Montana 1M, SinEcch 02 500mg Arnica Montana 12C",
    "parsed_interactions": [
      {
        "interacting_substance": "Talwin",
        "severity": "unknown",
        "description": "Do not take together with Talwin tm or Talwin NX tm"
      }
    ]
  },
  {
    "active_ingredient": "Benzalkonium Chloride 0.13% w/w",
    "parsed_interactions": [
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may diminish adrenal suppression by corticosteroids."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Substrates",
        "severity": "unknown",
        "description": "Hepatic Enzyme Inducers, Inhibitors and Substrates)."
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants, Oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Dexamethasone Suppression Test",
        "severity": "unknown",
        "description": "Dexamethasone Suppression Test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported."
      },
      {
        "interacting_substance": "Thus",
        "severity": "moderate",
        "description": "Thus, results of the DST should be interpreted with caution in these patients."
      },
      {
        "interacting_substance": "Digitalis Glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "Ephedrine",
        "severity": "minor",
        "description": "Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "Dexamethasone",
        "severity": "moderate",
        "description": "Dexamethasone is a moderate inducer of CYP 3A4."
      },
      {
        "interacting_substance": "Hepatic Enzyme Inducers, Inhibitors and Substrates",
        "severity": "minor",
        "description": "Co-adminstration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "unknown",
        "description": "In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-Inflammatory Agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "Thalidomide",
        "severity": "unknown",
        "description": "Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccination)."
      }
    ]
  },
  {
    "active_ingredient": "Hyoscyamus niger 3X, Nux moschata 4C, Passiflora incarnata 3X, Stramonium 6X",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Non-habit forming - No grogginess - no side effects - no drug interactions - works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Antimonium tartaricum 6C Bryonia alba 3C Coccus cacti 3C Drosera rotundifolia 3C Ipecacuanha 3C Pulsatilla 6C Rumex crispus 6C Spongia tosta 3C Sticta pulmonaria 3C",
    "parsed_interactions": [
      {
        "interacting_substance": "Safe",
        "severity": "unknown",
        "description": "Safe - Non drowsy - Dye Free - No drug interactions - Works naturally with your body"
      }
    ]
  },
  {
    "active_ingredient": "Acetyl Tetrapeptide-5 Acetyl Octapeptide-3",
    "parsed_interactions": [
      {
        "interacting_substance": "Interactions Oil",
        "severity": "unknown",
        "description": "Interactions Oil-based makeup may reduce the effectiveness of the product"
      }
    ]
  },
  {
    "active_ingredient": "Charcoal Powder, Simmondsia Chinensis (Jojoba) Seed Oil, Panthenol",
    "parsed_interactions": [
      {
        "interacting_substance": "Interactions No",
        "severity": "unknown",
        "description": "Interactions No interactions between this mask and other drugs or substances are known or suspected"
      }
    ]
  },
  {
    "active_ingredient": "Hyaluronic Acid",
    "parsed_interactions": [
      {
        "interacting_substance": "Interactions No",
        "severity": "unknown",
        "description": "Interactions No interactions between gengicure Â® gel and other drugs or substances are known or suspected."
      }
    ]
  },
  {
    "active_ingredient": "Bisacodyl 5mg",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interactions",
        "severity": "unknown",
        "description": "No specific drug interactions have been demonstrated."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 5 gr (325 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "moderate",
        "description": "Drug Interaction Precaution"
      },
      {
        "interacting_substance": "Drug Interaction Precaution Ask",
        "severity": "moderate",
        "description": "Drug Interaction Precaution Ask a physician or pharmacist before use if you are presently taking a prescription drug Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "(% by weight) Camphor 4% Menthol 10%",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The following drug interactions [sections 7.1 to 7.7] are noted for oral diclofenac sodium."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects including increased GAI bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "( 7.1 ) Concomitant use of anticoagulants and diclofenac have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "( 7.2 ) 7.1 Aspirin When diclofenac is administered with aspirin, the binding of diclofenac to protein is reduced, although the clearance of free diclofenac is not altered."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of diclofenac and aspirin is not generally recommended because of the potential of increased adverse effects."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "severe",
        "description": "7.2 Anticoagulants The effects of anticoagulants such as warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "7.3 ACE-Inhibitors NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "Consider this interaction in patients taking NSAIDs concomitantly with ACE-inhibitors."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "7.4 Diuretics Clinical studies, as well as postmarketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The response has been attributed to inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "moderate",
        "description": "During concomitant therapy with NSAIDs, observe the patient closely for signs of renal failure [ see Warnings and Precautions (5.6) ] , as well as to assure diuretic efficacy."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "7.5 Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "Thus, when NSAIDs, including diclofenac, and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "7.6 Methotrexate NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "This may indicate that they could enhance the toxicity of methotrexate."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "moderate",
        "description": "Use caution when NSAIDs, including diclofenac, are administered concomitantly with methotrexate."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "7.7 Cyclosporine Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Therefore, concomitant therapy with diclofenac may increase cyclosporine's nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "moderate",
        "description": "Use caution when diclofenac is administered concomitantly with cyclosporine."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "7.8 Oral Nonsteroidal Anti-Inflammatory Drugs Concomitant use of oral NSAIDs with diclofenac sodium topical solution has been evaluated in one Phase 3 controlled trial and in combination with oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "less than 1%), and more frequent abnormal creatinine (12% vs."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "12) and hemoglobin (13% vs."
      },
      {
        "interacting_substance": null,
        "severity": "minor",
        "description": "Therefore, do not use combination therapy with diclofenac sodium topical solution and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.9 Topical Treatments Instruct patients that before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medication to the same skin surface of the knee treated with diclofenac sodium topical solution, they must wait until the treated area is completely dry."
      }
    ]
  },
  {
    "active_ingredient": "17.1 Embryofetal Toxicity Pregnancy loss and malformations Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. Advise that they must use an acceptable form of contraception [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ]. Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate [see Use in Specific Populations (8.1) ]. Contraception Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential [see Use in Specific Populations (8.3) ]. Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence . Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended [see Use in Specific Populations (8.3) ]. For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient. Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies [see Use in Specific Populations (8.3) , Nonclinical Toxicology (13.1) ].",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.1) Mycophenolate mofetil may reduce effectiveness of oral contraceptives."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "Use of additional barrier contraceptive methods is recommended."
      },
      {
        "interacting_substance": "DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce Mycophenolate mofetil efficacy",
        "severity": "unknown",
        "description": "(7.2) See FPI for other important drug interactions."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "unknown",
        "description": "(7) 7.1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration."
      },
      {
        "interacting_substance": "PPIs",
        "severity": "unknown",
        "description": "Proton Pump Inhibitors (PPIs) Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Enterohepa",
        "severity": "unknown",
        "description": "Examples Lansoprazole, pantoprazole Drugs that Interfere with Enterohepa tic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Examples Trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of mycophenolate mofetil related adverse reactions."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil."
      },
      {
        "interacting_substance": "Examples Telmisartan",
        "severity": "unknown",
        "description": "Examples Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation)."
      },
      {
        "interacting_substance": "Calcium Free Phosph",
        "severity": "unknown",
        "description": "Calcium Free Phosph ate Binders Clinical Impact Concomitant use with calcium free phosphate binders decrease MPA systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce mycophenolate mofetil efficacy."
      },
      {
        "interacting_substance": "Management Administer",
        "severity": "unknown",
        "description": "Prevention or Management Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil."
      },
      {
        "interacting_substance": "Mycophenolate Mofetil",
        "severity": "minor",
        "description": "Examples Sevelamer 7.2 Effect of Mycophenolate Mofetil on Other Drugs Table 8 Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs Drugs that Undergo Renal Tubular Secretion Clinical Impact When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs."
      },
      {
        "interacting_substance": "Management Monitor",
        "severity": "unknown",
        "description": "Prevention or Management Monitor for drug-related adverse reactions in patients with renal impairment."
      },
      {
        "interacting_substance": "Examples Acyclovir",
        "severity": "unknown",
        "description": "Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir Combination Oral Contraceptives Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3) ] , which may result in reduced combination oral contraceptive effectiveness."
      },
      {
        "interacting_substance": "Management Use",
        "severity": "unknown",
        "description": "Prevention or Management Use additional barrier contraceptive methods."
      }
    ]
  },
  {
    "active_ingredient": "Menthol USP 3%, Camphor USP 3%",
    "parsed_interactions": [
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding."
      },
      {
        "interacting_substance": "anticoagulants",
        "severity": "severe",
        "description": "The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone."
      },
      {
        "interacting_substance": "Serotonin",
        "severity": "unknown",
        "description": "Serotonin release by platelets plays an important role in hemostasis."
      },
      {
        "interacting_substance": "Case",
        "severity": "minor",
        "description": "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Monitor patients with concomitant use of diclofenac sodium delayed-release with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "major",
        "description": "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "moderate",
        "description": "Concomitant use of diclofenac sodium delayed-release and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see PRECAUTIONS; Hematological Toxicity ) ."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Diclofenac sodium delayed-release is not a substitute for low dose aspirin for cardiovascular protection."
      },
      {
        "interacting_substance": "Blockers",
        "severity": "unknown",
        "description": "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-"
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol)."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure."
      },
      {
        "interacting_substance": "These",
        "severity": "unknown",
        "description": "These effects are usually reversible."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained."
      },
      {
        "interacting_substance": "ACE",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "Intervention",
        "severity": "unknown",
        "description": "When these drugs are administered concomitantly, patients should be adequately hydrated."
      },
      {
        "interacting_substance": "Assess",
        "severity": "unknown",
        "description": "Assess renal function at the beginning of the concomitant treatment and periodically thereafter."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients."
      },
      {
        "interacting_substance": "Diuretics Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity and Hyperkalemia ) ."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin."
      },
      {
        "interacting_substance": "digoxin",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and digoxin, monitor serum digoxin levels."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%."
      },
      {
        "interacting_substance": "Lithium Clinical Impact",
        "severity": "unknown",
        "description": "This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis."
      },
      {
        "interacting_substance": "lithium",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and lithium, monitor patients for signs of lithium toxicity."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "minor",
        "description": "Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction)."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and methotrexate, monitor patients for methotrexate toxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and cyclosporine may increase cyclosporineâ€™s nephrotoxicity."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and cyclosporine, monitor patients for signs of worsening renal function."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation ) ."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "minor",
        "description": "Concomitant use of diclofenac sodium delayed-release and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)."
      },
      {
        "interacting_substance": "pemetrexed",
        "severity": "unknown",
        "description": "During concomitant use of diclofenac sodium delayed-release and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "unknown",
        "description": "NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed."
      },
      {
        "interacting_substance": "nsaids",
        "severity": "minor",
        "description": "In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration."
      },
      {
        "interacting_substance": "Diclofenac",
        "severity": "unknown",
        "description": "Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "Co-administration of diclofenac with CYP2C9 inhibitors (e.g."
      },
      {
        "interacting_substance": "CYP",
        "severity": "minor",
        "description": "voriconazole) may enhance the exposure and toxicity of diclofenac whereas coadministration with CYP2C9 inducers (e.g."
      },
      {
        "interacting_substance": "Clinical Impact",
        "severity": "minor",
        "description": "rifampin) may lead to compromised efficacy of diclofenac."
      },
      {
        "interacting_substance": "CYP",
        "severity": "unknown",
        "description": "A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics ) ."
      }
    ]
  },
  {
    "active_ingredient": "(in each tablet) Sodium bicarbonate 5 gr (325 mg)",
    "parsed_interactions": [
      {
        "interacting_substance": "Drug Interaction Precaution",
        "severity": "moderate",
        "description": "Drug Interaction Precaution"
      },
      {
        "interacting_substance": "Drug Interaction Precaution Ask",
        "severity": "moderate",
        "description": "Drug Interaction Precaution Ask a physician or pharmacist before use if you are presently taking a prescription drug Antacids may interact with certain prescription drugs"
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Active ingredient",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis."
      },
      {
        "interacting_substance": "Iodinated",
        "severity": "minor",
        "description": "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function."
      },
      {
        "interacting_substance": "Stop",
        "severity": "unknown",
        "description": "Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable."
      },
      {
        "interacting_substance": "Radioactive Iodine Administration",
        "severity": "unknown",
        "description": "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The decrease in efficacy lasts for 6 to 8 weeks."
      },
      {
        "interacting_substance": "Beta",
        "severity": "unknown",
        "description": "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions, and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "Because of the risk of hypersensitivity reactions, use caution when administering iodixanol to patients taking beta-blockers."
      },
      {
        "interacting_substance": "Oral Cholecystographic Contrast Agents Renal",
        "severity": "unknown",
        "description": "Oral Cholecystographic Contrast Agents Renal toxicity has been reported in patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular iodinated contrast agents."
      },
      {
        "interacting_substance": "Postpone",
        "severity": "unknown",
        "description": "Postpone the administration of iodixanol in patients who have recently received an oral cholecystographic contrast agent."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "7.2 Drug-Laboratory Test Interactions Effect on Thyroid Tests The results of protein bound iodine and radioactive iodine uptake studies, which depend on iodine estimation, will not accurately reflect thyroid function for at least 16 days following administration of iodinated contrast agents."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, thyroid function tests which do not depend on iodine estimations (e.g., T3 resin uptake and total or free thyroxine T4 assays) are not affected."
      },
      {
        "interacting_substance": "Effect",
        "severity": "unknown",
        "description": "Effect on Urine Tests As reported with other contrast agents, iodixanol may produce a false-positive result for protein in the urine using urine dip tests."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, the Coomassie blue method has been shown to give accurate results for the measurement of urine protein in the presence of iodixanol."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "In addition, care should be used in interpreting the results of urine specific gravity measurements in the presence of high levels of iodixanol and other contrast agents in the urine."
      },
      {
        "interacting_substance": "Refractometry",
        "severity": "unknown",
        "description": "Refractometry or urine osmolality may be substituted."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B Injection and Potassium-Depleting Agents When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance."
      },
      {
        "interacting_substance": "anticholinesterases",
        "severity": "severe",
        "description": "Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Anticoagulants, Oral Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "antidiabetics",
        "severity": "minor",
        "description": "Antidiabetics Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Antitubercular Drugs Serum",
        "severity": "unknown",
        "description": "Antitubercular Drugs Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine Cholestyramine may increase the clearance of corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis Glycosides Patients",
        "severity": "minor",
        "description": "Digitalis Glycosides Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "Strong CYP",
        "severity": "unknown",
        "description": "Interactions with Strong CYP3A4 Inhibitors Corticosteroids (including betamethasone) are metabolized by CYP3A4."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "Coadministration",
        "severity": "minor",
        "description": "Coadministration with other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased exposures of corticosteroids and therefore the potential for increased risk of systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "Consider",
        "severity": "minor",
        "description": "Consider the benefit of coadministration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal Anti-inflammatory Agents (NSAIDS) Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Skin Tests Corticosteroids",
        "severity": "unknown",
        "description": "Skin Tests Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Vaccines Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS, Infections, Vaccination section)."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": null,
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": null,
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Purpose Povidone Iodine 10% w/v (9.85% w/w/) Antiseptic | Isopropyl Alcohol 70% v/v",
    "parsed_interactions": [
      {
        "interacting_substance": "DRUG INTERACTIONS Local Anesthetics",
        "severity": "unknown",
        "description": "The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Monitor",
        "severity": "unknown",
        "description": "Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "contraindicated",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants",
        "severity": "unknown",
        "description": "( 5.6 , 7.2 ) Ergot-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Type Oxytocic Drugs",
        "severity": "unknown",
        "description": "( 5.6 , 7.3 ) Nonselective Beta-"
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Adrenergic Antagonists",
        "severity": "unknown",
        "description": "( 5.6 , 7.4 )"
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "minor",
        "description": "Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs."
      },
      {
        "interacting_substance": "Serious",
        "severity": "severe",
        "description": "Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "( 5.13 , 7.6 ) 7.1 Local Anesthetics The toxic effects of local anesthetics are additive."
      },
      {
        "interacting_substance": "Bupivacaine Hydrochloride Injection",
        "severity": "moderate",
        "description": "If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Dosage and Administration (2.1) , Warnings and Precautions (5.2) ] ."
      },
      {
        "interacting_substance": "Tricyclic Antidepressants The",
        "severity": "contraindicated",
        "description": "7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see Warnings and Precautions (5.6) ] ."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.3 Ergot-Type Oxytocic Drugs Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      },
      {
        "interacting_substance": "Epinephrine",
        "severity": "moderate",
        "description": "Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "severe",
        "description": "7.4 Nonselective Beta-Adrenergic Antagonists Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia."
      },
      {
        "interacting_substance": "Potent Inhalation Anesthetics",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "Precautions",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions (5.6) ]."
      },
      {
        "interacting_substance": "Methemoglobinemia Patients",
        "severity": "moderate",
        "description": "7.5 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics [see Warnings and Precautions (5.3) ] ."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "severe",
        "description": "Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine 7.6 Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions (5.13) ] ."
      },
      {
        "interacting_substance": "Butyrophenones Phenothiazines",
        "severity": "unknown",
        "description": "7.7 Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "Epinephrine Injection",
        "severity": "unknown",
        "description": "Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided."
      },
      {
        "interacting_substance": "Examples of Drugs Associated with Methemoglobinemia",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "aminoglutethimide",
        "severity": "minor",
        "description": "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression."
      },
      {
        "interacting_substance": "diuretics",
        "severity": "unknown",
        "description": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia."
      },
      {
        "interacting_substance": "amphotericin b",
        "severity": "unknown",
        "description": "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure."
      },
      {
        "interacting_substance": "antibiotics",
        "severity": "major",
        "description": "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see"
      },
      {
        "interacting_substance": "Concomitant",
        "severity": "severe",
        "description": "Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis."
      },
      {
        "interacting_substance": "Anticholinesterases",
        "severity": "unknown",
        "description": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy."
      },
      {
        "interacting_substance": "warfarin",
        "severity": "unknown",
        "description": "Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports."
      },
      {
        "interacting_substance": "Anticoagulants , oral",
        "severity": "unknown",
        "description": "Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect."
      },
      {
        "interacting_substance": "Antidiabetics",
        "severity": "minor",
        "description": "Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required."
      },
      {
        "interacting_substance": "Serum",
        "severity": "unknown",
        "description": "Serum concentrations of isoniazid may be decreased."
      },
      {
        "interacting_substance": "cholestyramine",
        "severity": "minor",
        "description": "Cholestyramine may increase the clearance of oral corticosteroids."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "unknown",
        "description": "Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently."
      },
      {
        "interacting_substance": "Convulsions",
        "severity": "unknown",
        "description": "Convulsions have been reported with this concurrent use."
      },
      {
        "interacting_substance": "Digitalis glycosides",
        "severity": "minor",
        "description": "Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia."
      },
      {
        "interacting_substance": "estrogens",
        "severity": "minor",
        "description": "Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "minor",
        "description": "Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "minor",
        "description": "Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin): Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids."
      },
      {
        "interacting_substance": "ketoconazole",
        "severity": "major",
        "description": "Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "minor",
        "description": "Nonsteroidal anti-inflammatory drugs (NSAIDs) : Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects."
      },
      {
        "interacting_substance": "aspirin",
        "severity": "unknown",
        "description": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia."
      },
      {
        "interacting_substance": "Ketoconazole",
        "severity": "unknown",
        "description": "The clearance of salicylates may be increased with concurrent use of corticosteroids."
      },
      {
        "interacting_substance": "Corticosteroids",
        "severity": "unknown",
        "description": "Corticosteroids may suppress reactions to skin tests."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines."
      },
      {
        "interacting_substance": "vaccines",
        "severity": "unknown",
        "description": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see"
      },
      {
        "interacting_substance": "Infections",
        "severity": "unknown",
        "description": "Infections, Vaccinations )."
      },
      {
        "interacting_substance": "Phenothiazines",
        "severity": "unknown",
        "description": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "unknown",
        "description": "Concurrent use of these agents should generally be avoided."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "moderate",
        "description": "In situations when concurrent therapy is necessary, careful patient monitoring is essential."
      },
      {
        "interacting_substance": "WARNINGS",
        "severity": "severe",
        "description": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."
      }
    ]
  },
  {
    "active_ingredient": "Each one gram contains: Lactic acid 167mg and salicylic acid 167mg.",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions No interaction betyween Lactic acid and Salicylic acid and other drugs or substances are known or suspected."
      }
    ]
  },
  {
    "active_ingredient": "Acetaminofen Dextromethorphan HBr Phenylephryne HCL Chlorpheniramine Maleate",
    "parsed_interactions": [
      {
        "interacting_substance": null,
        "severity": "unknown",
        "description": "Drug Interactions Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI), (Certain drugs for depression, psychiatric or emotional conditions, or Parkinsons disease) or for 2 weeks after stopping that MAOI drug, if you are uncertain whether your prescription drug contains an MAOI, consult a health professional before taking this product"
      }
    ]
  },
  {
    "active_ingredient": "Benzalkonium Chloride, 0.13% w/v",
    "parsed_interactions": [
      {
        "interacting_substance": "Except",
        "severity": "contraindicated",
        "description": "Except in life-threatening situations, avoid this combination."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine."
      },
      {
        "interacting_substance": "lithium",
        "severity": "minor",
        "description": "Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "severe",
        "description": "Furosemide combined with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "An interruption or reduction in the dosage of furosemide, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers may be necessary."
      },
      {
        "interacting_substance": "Potentiation",
        "severity": "unknown",
        "description": "Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide may decrease arterial responsiveness to norepinephrine."
      },
      {
        "interacting_substance": "However",
        "severity": "unknown",
        "description": "However, norepinephrine may still be used effectively."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "The intake of furosemide and sucralfate should be separated by at least two hours."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Use of furosemide concomitantly with chloral hydrate is therefore not recommended."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "Phenytoin interferes directly with renal action of furosemide."
      },
      {
        "interacting_substance": "phenytoin",
        "severity": "unknown",
        "description": "There is evidence that treatment with phenytoin leads to decreased intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations."
      },
      {
        "interacting_substance": "methotrexate",
        "severity": "major",
        "description": "Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "minor",
        "description": "Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment."
      },
      {
        "interacting_substance": "cyclosporine",
        "severity": "minor",
        "description": "Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Literature reports indicate that co-administration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis."
      },
      {
        "interacting_substance": "Indomethacin",
        "severity": "unknown",
        "description": "Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation."
      },
      {
        "interacting_substance": "furosemide",
        "severity": "unknown",
        "description": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved."
      }
    ]
  }
]